EmbarkNeuro  Clinical Study Protocol  
ANC -501 ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 1 of 63 CLINICAL STUDY PROTOCOL  
Protocol Title:  A Phase 2 Study of ANC-501 in the Treatment of  Adults with 
Major Depressive Disorder  
Protocol Number:  ANC501D0005 
Study Drug:  ANC -501 
Brief Title:  ANC -501 in Adults with Major Depressive Disorder  
Phase of Development:  2 
Sponsor Name and Address : Ancora Bio  d/b/a EmbarkNeuro, Inc.  
1111 Broadway 
Suite 1300 Oakland, CA  95607 
Sponsor Contact: Philip Perera ,
  MD,  MBA  
Chief Medical Officer  
philip.perera@embarkneuro.com  
Regulatory Agency Identifier Number(s):  IND 119048 
Version Number:  Date  
Protocol Version 6.0, Amendment 05 03 March 2023 
Protocol Version 5.0, Amendment 04 17 January 2023 
Protocol Version 4.0, Amendment 03 21 November 2022 
Protocol Version 3.0, Amendment 02 22 August 2022 
Protocol Version 2.0, Amendment 01 04 May 2022 
Original Protocol 1.0 09 March 2022 

EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 2 of 63 This clinical study will be conducted in accordance with the International Council for Harmonisation of  Technical 
Requirements for Pharmaceuticals for Human Use (ICH), Good Clinical Practice (GCP) Guidelines, and applicable 
regulatory requirements.  
CONFIDENTIALITY STATEMENT  
The confidential information in this document is provided to you as an Investigator or consul tant for review by you, 
your staff, and the applicable Institutional Review Board/Independent Ethics Committee. Your acceptance of this 
document constitutes agreement that you will not disclose the information contained herein to others without written 
authorization from the Sponsor.  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 3 of 63 PROTOCOL SIGNATURE PAGE  
 
Protocol: ANC501D0005 Version 6.0, Amendment  05 
 
I, the undersigned, have read this protocol and agree that it contains all necessary information 
required to conduct the study. 
 
  
 
Stephen J . Kanes , MD, PhD  
Chief Executive Officer  
EmbarkNeuro   Date  
 
DocuSign Envelope ID: 45242E7D-47EB-4423-B6F3-40A97577BF93
07-Mar-2023

EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 4 of 63 INVESTIGATOR SIGNATURE  
By signing below, I agree that:  
I have read this protocol. I agree that it contains all necessary details for carrying out the study as 
described. I will conduct this study in accordance with the design and specific provisions  of this 
protocol. I will not initiate the study until it has received approval from the I nstitutional R eview 
Board/Independent Ethics Committee. I will provide copies of this protocol and access to all 
information furnished by EmbarkNeuro to study personnel under my supervision. I will discuss this material with them to ensure they are fully informed about the study drug  and study 
procedures. I  will inform them that  this information is confidential and proprietary to 
EmbarkNeuro  and that m ay not be further disclosed to third parties. I understand that the study 
may be terminated or enrollment suspended at any time by EmbarkNeuro with or without cause, or by me if it becomes necessary to protect the best interests of the study patients. 
I agree to conduct this study in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki, the International Council for Harmonisation guidelines for Good 
Clinical Practice, and applicable regional regulations.  
INVESTIGATOR SIGNATURE  
   
Investigator Signature   Date  
   
Investigator Printed Name    
  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 5 of 63 SUMMARY OF MAJOR PROTOCOL CHANGES  
 
Protocol 
Version  Summary of change  Rationale for change  
6.0, A05  Change inclusion # 8  Allows less restrictive MADRS cutoff 
score from minimum of 28 to minimum of 26  
6.0, A05  Change inclusion # 9  Allows screening of subjects with 
fewer weeks on continuous 
antidepressant therapy  
Broadens the types of concomitant antidepressants allowed  
6.0, A05  Change inclusion # 11  Allows less restrictive MADRS cutoff 
score from minimum of 28 to 
minimum of 26  
6.0, A05  Added clarification language for the screening period  Clarifies the restriction around 
medication changes during the screening period  
Clarifies the screening period does not 
need to be a full 30 days  
6.0, A05  Updated exclusion #22 to be consisten t with change in 
Inclusion #9  Clarifies the length of treatment on a stable dose prior to day1  
5.0, A04  Removed exclusion #5  Conforms with FDA IND advice  
5.0, A04  Updated exclusion #18 (previously #19) to indicate 
positive alcohol breath test  New exclusion #19 covers the urine drug screen  
5.0, A04  Added new exclusion #19 to clarify the positive urine 
drug test criteria  Offers specific guidance to 
investigators and no longer eliminates 
subjects with recreational cannabis use  
5.0, A04  Updated abbr eviation for CTQ  Reflects the appropriate 28 -Item CTQ 
used in this study  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 6 of 63 5.0, A04 Removed the word â€œcannabisâ€ from footnote â€˜gâ€™ in the 
Schedule of Events  Consistent with exclusion #19 
5.0, A04 Clarified footnote â€˜i' in the Schedule of Events Offers greater latitude for blood draw times  
4.0, A03 Updated Sponsor name throughout document from 
Ancora Bio to EmbarkNeuro Ancora Bio is now doing business as EmbarkNeuro 
4.0, A03 Clarified the conversion from nmol/L to mcg/L for 12 -
hour urine cortisol (>22.7 nmol/L = greater than or equal 
to 8.3 mcg/L).  
 Clarification  
4.0, A03 Clarification to that exclusion #16 history of seizures does 
not include isolated febrile seizures of childhood  Clarification  
4.0, A03 Clarification that the eye exam will be referred to as an 
ophthalmic exam instead of an ophthalmological exam since optometrists are now permitted into the study Clarification which conforms to the 
current standard of practice 
4.0, A03 The addition of an optometrist has been included along 
with an ophthalmologist  Conforms to the current standard of practice  
3.0, A02  
LOCS III scale changes from baseline in the LOCS III 
grade of â‰¥0.5 (Nuclear Opalescence), â‰¥0.5 (Cortical). â‰¥ 0.5 
(Posteri or Subcapsular) in either eye or any changes 
considered to be clinically significant (e.g., incidence of cataract) will be reported as an adverse event and as an 
event of special interest. Response to FDA comments 
3.0, A02 Clarifi ed C-SSRS exclusion crite rion #2 Clarification to the critical questions and the timeframe.  
3.0 A02 Clarification of  trained personnel qualified to administer 
Ophthalmic exam  and slit -lamp imaging  Conforms to the current standard of care 
3.0 A02 Addition of Dosing Diary Improves ability to monitor study drug accountability and compliance  
2.0, A01 Updated list of abbreviations To reflect the updates deleted and added, as applicable  
2.0, A01 Updated follow-up visits to include Day 112 for all subjects Response to FDA comm ents 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 7 of 63 2.0, A01  Updated method of alcohol test at screening  Clarification  
2.0, A01  Updated list of scales patients will be completing  Clarification  
2.0, A01  Change from AREDS to LOCS III grading scale to detect 
changes in lens opacities  Response to FDA comments  
2.0, A01  Added word â€œemergentâ€ to the C -SSRS endpoint  Clarification  
2.0, A01  Updated inclusion #4 to include BCVA and clarify what is 
meant by significant findings  Clarification  
2.0, A01  Updated Exclusion #1 to include current MDD episode  Clarification  
2.0, A01  Added new Exclusion (now #5) for History of 
implantation of an artificial lens or missing lens in one or 
both eyes  Improves ability to identify risk of 
lens opacity  
2.0, A01  Added new Exclusion (now #6) to read as follows  
Based on an ophthalmic examination performed at 
Screening, patient must not have any of the following:  
â€¢ Nuclear opalescence (NO) with a LOCSIII 
classification > 3.0 in either eye  
â€¢ Nuclear color (NC) with a LOCSIII 
classification > 3.5 in either eye  
â€¢ Cortical lens opacities (C) with a LOCSIII classification > 2.0 in either eye  
â€¢ Posterior subcapsular lens opacities (P) with a 
LOCSIII classification > 0.3 in either  Response to FDA comments  
2.0, A01  Updated Exclusion #18 to remove benzodiazepines from 
exclusion  Clarification  
2.0, A01  Updated Exclusion #19 to clarify method and type drug tests at screening  Clarified breath test or urine drug screen  
2.0, A01  Updated Schedule of Events to reflect other updates in 
this Summary of Changes  Clarification  
2.0, A01  Include HAMD -6 and GAD- 7 as exploratory endpoints  Would like to assess patient reported 
changes in depression and anxiety 
symptoms  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 8 of 63 2.0, A01  Included Section 8.4.9 to include Events of Special 
Interest â€“ Lens Opacity  Response to FDA comments  
2.0, A01  Remo ved mention of Local laboratories  Clarification  
2.0, A01  Removed use of AiCure platform throughout the 
document  AiCure no longer being used for drug 
adherence  
2.0, A01  Administration changes/corrections throughout  Clarifications/corrections  
 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 9 of 63 TABLE OF CONTENTS  
CLINICAL STUDY PROTOCOL  ..................................................................................................1  
CONFIDENTIALITY STATEMENT  .............................................................................................2  
PROTOCOL SIGNATURE PAGE  .................................................................................................3  
INVESTIGATOR SIGNATURE .....................................................................................................4  
SUMMARY OF MAJOR PROTOCOL CHANGES  ......................................................................5  
LIST OF ABBREVIATIONS  ........................................................................................................13  
1. PROTOCOL SUMMARY ..........................................................................................16  
1.1. Synopsis ......................................................................................................................16  
1.2. Study Schema .............................................................................................................23  
1.3. Schedule of Events .....................................................................................................24  
2. INTRODUCTION  ......................................................................................................28  
2.1. Major Depressive Disorder  .........................................................................................28  
2.2. Mechanism of Action of Vasopressin Receptor 1b (V1b Receptor) ..........................29  
2.3. Rationale for Targeting V1b Receptor in Treatment of Depression ...........................29  
2.3.1.  Evaluation in Humans .................................................................................................30  
2.4. Risk/Benefit ................................................................................................................31  
3. OBJECTIVES AND ENDPOINTS  ............................................................................33  
4. STUDY DESIGN  .......................................................................................................34  
4.1. Overall Design  ............................................................................................................34  
4.2. Justification for Dose ..................................................................................................36  
4.3. End of Study Definition ..............................................................................................36  
5. STUDY POPULATION  .............................................................................................37  
5.1. Inclusion Criteria  ........................................................................................................37  
5.2. Exclusion Criteria  .......................................................................................................38  
5.3. Subject Enrollment .....................................................................................................39  
5.4. Screen Failures  ............................................................................................................40  
6. STUDY TREATMENT  ..............................................................................................41  
6.1. Study Treatment Administered  ...................................................................................41  
6.2. Handling, Storage, and Accountability .......................................................................41  
6.3. Measures to Minimize Bias: Randomization and Blinding  ........................................41  
6.4. Treatment Compliance  ................................................................................................41  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 10 of 63 6.5. Dose Modifications .....................................................................................................41  
6.6. Continued Access to Study Drug after the End of Study ...........................................42  
6.7. Treatment of Overdose  ...............................................................................................42  
6.8. Concomitant Medications and Therapies ...................................................................42  
7. DISCONTINUATION OF STUDY TREATMENT AND SUBJECT 
WITHDRAWAL  ........................................................................................................43  
7.1. Discontinuation of Study Treatment ...........................................................................43  
7.2. Subject Withdrawal from Study .................................................................................43  
8. STUDY ASSESSMENTS AND PROCEDURES  ......................................................44  
8.1. General Study Assessments  ........................................................................................44  
8.2. Efficacy Assessments  .................................................................................................44  
8.3. Safety Assessments  .....................................................................................................45  
8.3.1.  Laboratory Assessments .............................................................................................46  
8.3.1.1.  Reporting and Evaluation of Laboratory Test Results  ...............................................47  
8.3.1.2.  Repeat Testing  ............................................................................................................47  
8.3.2.  COVID-19 Pandemic Accommodations ....................................................................48  
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting .....................48  
8.4.1.  Definition of Adverse Event .......................................................................................48  
8.4.1.1.  Events Meeting the Adverse Event Definition ...........................................................49  
8.4.1.2.  Events NOT Meeting the Adverse Event Definition ..................................................49  
8.4.2.  Definition of Serious Adverse Event (SAE) ...............................................................50  
8.4.3.  Time Period for Collecting AE and SAE Information ...............................................51  
8.4.4.  Recording of Adverse Events and/or Serious Adverse Events ...................................51  
8.4.4.1.  Terms of Reported Adverse Events ............................................................................51  
8.4.4.2.  Detection of Adverse Events and Serious Adverse Events ........................................51  
8.4.4.3.  Severity of Adverse Events ........................................................................................51  
8.4.4.4.  Causal Relationship with Study Treatment ................................................................51  
8.4.4.5.  Follow-up of Adverse Events .....................................................................................52  
8.4.5.  Reporting of Serious Adverse Events (SAE) ..............................................................52  
8.4.6.  Reporting of Deaths ....................................................................................................53  
8.4.7.  Pregnancy  ...................................................................................................................53  
8.4.8.  Overdose .....................................................................................................................53  
8.4.9.  Events of Special Interest - Lens Opacity  ....................................................................53  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 11 of 63 8.5. Pharmacokinetics  ........................................................................................................53  
8.6. Biomarker Evaluations ...............................................................................................54  
9. STATISTICAL CONSIDERATIONS  .......................................................................55  
9.1. Statistical Hypotheses  .................................................................................................55  
9.2. Sample Size Determination  ........................................................................................55  
9.3. Analysis Populations ..................................................................................................55  
9.4. Statistical Analyses  .....................................................................................................55  
9.4.1.  General Considerations ...............................................................................................55  
9.4.2.  Analysis of Safety  .......................................................................................................55  
9.4.3.  Analysis of Efficacy  ...................................................................................................56  
9.4.4.  Analysis of Pharmacokinetics  .....................................................................................56  
9.5. Interim Analysis  ..........................................................................................................56  
10. ADMINISTRATIVE CONSIDERATIONS  ..............................................................57  
10.1.  Protocol Compliance/Deviations ................................................................................57  
10.2.  Study Termination ......................................................................................................57  
10.3.  Case Report Forms  .....................................................................................................57  
10.4.  Source Documents ......................................................................................................57  
10.5.  Data Protection  ...........................................................................................................58  
10.6.  Recordkeeping ............................................................................................................58  
10.7.  Quality Control and Quality Assurance ......................................................................58  
10.8.  Financial Disclosure  ...................................................................................................58  
11. ETHICS  ......................................................................................................................60  
11.1.  Ethical Conduct of the Study ......................................................................................60  
11.2.  Written Informed Consent ..........................................................................................60  
11.3.  Institutional Review Board/Independent Ethics Committee  ......................................60  
12. PUBLICATION POLICY ..........................................................................................61  
13. REFERENCES  ...........................................................................................................62  
 
LIST OF TABLES  
Table 1:  General Study Assessments  ........................................................................................44  
Table 2:  Efficacy Assessments  .................................................................................................45  
Table 3:  Safety Assessments  .....................................................................................................45  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 12 of 63 Table 4:  Laboratory Assessments .............................................................................................46  
Table 5:  Definitions of Analysis Populations ...........................................................................55  
 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 13 of 63 LIST OF ABBREVIATIONS  
Abbreviation  Term  
ACTH  adrenocorticotropic hormone  
ADT  antidepressant therapy  
AE adverse event  
ALT  alanine aminotransferase  
aPTT activated partial thromboplastin time  
AST  aspartate aminotransferase  
AUC  area under the concentration -time curve  
AVP  arginine vasopressin  
BCVA  best corrected visual acuity  
BMI  body mass index  
BUN  blood urea nitrogen  
CGI-I Clinical Global Impression -Improvement  
CGI-S Clinical Global Impression -Severity  
CL r renal clearance  
Cmax  maximum plasma concentration  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -19 coronavirus disease 2019  
CRF  corticotropin- releasing factor  
CRH  corticotropin- releasing hormone  
CRO  clinical research organization  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CTQ  Childhood Trauma Questionnaire  
CYP  cytochrome P450  
DSM -IV Diagnostic and Statistical Manual of Mental Disorders, fourth edition  
ECG  electrocardiogram  
eCRF  electronic case report form  
ECT  electroconvulsive therapy  
EMA  Ecological Momentary Assessment  
ENT  ears, nose, and throat  
ET early termination  
FDA Food and Drug Administration  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 14 of 63 Abbreviation  Term  
GAD- 7 General Anxiety Disorder (7- item)  
GCP  Good Clinical Practice  
HAM -A Hamilton Anxiety Scale  
HAMD- 6 Hamilton Depression Rating Scale (6 -item)  
HBsAg  hepatitis B surface antigen  
HCV Ab  hepatitis C virus antibody  
HIPAA  Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
HPA hypothalamus -pituitary -adrenal  
IB Investigatorâ€™s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IND Investigational N ew D rug 
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
LOCS III  Lens Opacities Classification System III  
MAD multiple ascending dose  
MADRS  Montgomery- Ã…sberg Depression Rating Scale  
MDD major depressive disorder  
MedDRA  Medical Dictionary for Regulatory Activities  
MGH Massachusetts General Hospital  
MGH ATRQ Massachusetts General Hospital Antidepressant Treatment Response 
Questionnaire  
mRNA messenger RNA  
NO Nuclear Opalescence  
PET positron emission tomography 
PGI-I Patient Global Impression of Improvement  
PK pharmacokinetic(s)  
PT Preferred Term ; prothrombin time  
RBC Red blood cell(s)  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 15 of 63 Abbreviation  Term  
rTMS  repetitive transcranial magnetic stimulation  
SAD single ascending dose  
SAE  serious adverse event  
SAFER  State vs trait, Assessability, Face and  Ecological validity, Rule of 3Ps [pervasive, 
persistent, and pathological]  
SAP Statistical Analysis Plan  
SCID -5-CT Structured Clinical Interview for DSM -5 â€“ Clinical Trials Version  
SF-36 Short Form -Health Survey  (36-item)  
SNRI  serotonin norepinephrine reuptake inhibitor  
SOC  System Organ Class  
SSRI  selective serotonin reuptake inhibitor  
STAR*D  Sequenced Treatment Alternatives to Relieve Depression  
tÂ½ apparent half -life 
TRD  treatment -resistant depression  
US United States  
V1b vasopressin receptor 1b  
WBC white blood cell(s)  
 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 16 of 63 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Sponsor:  EmbarkNeuro  
Study Title:  A Phase 2 Study of ANC -501 in the Treatment of Adults with Major Depressive Disorder  
Protocol Number:  ANC501D0005  Phase of Development:  2 
Investigational 
Product:  ANC -501 Capsules  
Study Design and Duration:  This is a single -arm, open- label Phase 2 study to assess the safety, tolerability, 
pharmacokinetics (PK), and efficacy of ANC -501 oral capsules as adjunctive treatment in 
subjects diagnosed with major depressive disorder (MDD).  
With the exception of subjects permitted to use current stable antidepressant treatment, initiation of psychotropic medications and other medications that may potentially have an impact on efficacy or safety endpoints will not be allowed between screening and completion of the Day 56 assessments. Psychotropic medications, which must have been initiated at least 8 weeks  prior to screening, must remain at a stable dose until completion 
of the Day 56 assessments. During the study, e fficacy and safety assessments will be 
performed and blood samples collected for PK analysis of ANC -501and future exploratory 
biomarker and genetic analysis . A wearable watch -like device will collect data on 
biometrics, which may be used for exploratory analyses.  
Subjects will receive 50 mg ANC -501 Capsules (5 Ã— 10 mg capsules) orally once daily at 
least 1 hour prior to the morning meal for 8 weeks beginning with the first dose 
administered in the clinic on Day 1 and will return to the clinic for scheduled visits on 
Days 8, 15, 29, 43, and 56. F ollow -up visit s will occur on Day 70 and 112. All visits after 
Day 1 allow a visit window of Â±3 days. 
Total duration of participation is 20 weeks  (up to 30 days screening, 8 weeks dosing, 8 
weeks follow -up). 
The following is a n overview of study procedures/ assessments  (refer to the Schedule of 
Events [ Section  1.3] for specific procedures/ assessments and  their timing, with further 
details located in  Section  
8): 
Screening Period (Day -30 to Day -1) 
After providing informed consent, eligibility assessments will include review of 
demographics, medical history, prior/concomitant medications, full physical examination, 
vital sign assessments, body weight/height/body mass index ( BMI ) measurements, urine 
pregnancy test (for female subjects of childbearing potential), urine drug and alcohol breath 
test screen, safety laboratory tests  (i.e., hematology, serum chemistry, coagulation, and 
urinalysis) , hep atitis and human immunodeficiency virus (HIV) screen, and plas ma, urine  
and saliva  cortisol collection . 
The Structured Clinical Interview for DSM -5 â€“ Clinical Trials Version (SCID -5-CT) will 
be employed for the determination of MDD and will be performed by a qualified, trained, 
validated healthcare professional.  
Qualified staff will also complete the Montgomery -Ã…sberg Depression Rating Scale 
(MADRS), Hamilton Anxiety Rating Scale (HAM -A), Clinical Global Impression -Severity 
(CGI -S), Columbia -Suicide Severity Rating Scale (C -SSRS), and Childhood Trauma 
Questionnaire (CTQ).  
Ophthalmic exams, including slit- lamp imaging, may be performed by an appropriately 
trained and qualified  individual as delegated by the PI and documented in the Study 
Delegation Log. However, a licensed ophthalmologist or optometrist must oversee this 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 17 of 63 work and will make the determination on subject eligibility as per inclusion criteria #4 .  Slit 
lamp imaging of the lens of both eyes will be taken and sent to a centra l reader for 
assessment using the LOCS III classification . 
 
Study site personnel will dispense equipment for 12- hour urine collection to measure 
cortisol levels . 
A call between the subject and the qualified central rater will be scheduled to allow the 
rater to administer the Massachusetts General Hospital Antidepressant Treatment Response 
Questionnaire (MGH ATRQ) for assessment of current antidepressant therapy (ADT), 
adequacy of duration and dose of prior and current ADT, as well as degree of 
improvement, to ensure only patients with inadequate response (<50% improvement) are 
included. The central rater will also complete the MADRS assessment and SAFER inventory (State vs trait, A ssessability, Face and Ecological validity, Rule of 3Ps  
[pervasive, persistent, and pathological] ) for confirmation of eligibility (diagnosis, severity, 
and treatment history). Results will be communicated to the site prior to Day 1.  
No changes to medications  are allowed during the screening period, a nd screen ing can be 
less than 30 days if all other criteria are met . 
 
Treatment Period (Day s 1, 8, 15, 29, 43, 56 ) 
At the Day 1 visit only, s ubjects confirmed as eligible will receive a 50 mg dose of study 
drug prior to eating. Subjects who cannot tolerate 50 mg will receive 40 mg for the 
remainder  of the study. Subjects who cannot tolerate 40 mg will be terminated from the 
study. Before releas ing subjects, study site personnel will dispense and train subjects on a 
dosing diary, the wearable watch -like device  and mobile application. ANC -501 will be 
dispensed to subjects with instructions to take the medication every morning at least 1 hour prior  to eating breakfast.  
During visits, safety procedures/assessments and administration of assessments/scales (including from Day 8 onward, the Clinical Global Impression- Improvement [CGI- I] and 
the Patient Global Impression of Improvement [PGI -I]) will be c onducted. During specific 
visits, PK blood samples will be collected, as well as b lood samples for future exploratory 
biomarker and genetic analysis . Concomitant  medications and dosing diary will be 
reviewed, the dosing diary will be returned to the subjec t, and adverse events (AEs) 
recorded. At all visits after Day 1, recording/accounting for any returned/unused ANC -501 
will be performed  and ANC -501 will be dispensed to subjects with a reminder to take the 
medication every morning at least 1 hour prior to eating breakfast.  
At home activities  
Subjects will take study medication every morning (at least 1 hour prior to eating breakfast) , make entries into  the dosing diary,  and wear their watch -like device  
throughout the day and night except when charging. Subjects will also complete 
EMA orienting questions,  the Hamilton Depression Rating Scale (6 -item) 
(HAMD- 6) and the  General Anxiety Disorder (7- item) (GAD -7) twice a day for 
three days per week , and the Short Form -Health Survey (36 -item) (SF -36) weekly  
using the EMA Wellness smartphone/tablet application.  
At the Day 43 visit, s tudy site personnel will dispense equipmen t and retrain subjects on 
the 12-hour urine collection to measure cortisol levels (the collection will be returned to the 
site at the Day  56 visit) . On Day 54, the site will contact  the subject to remind them to 
begin collection on Day 55.  
At the Day 56 visit, subjects will take their last study medication and visit the site to return 
their 12-hour urine collection,  all remaining medication , the dosing diary,  and wearable 
watch -like devices . Study procedures/assessments will be conducted, including an 
ophthalmic exam  and slit lamp  imaging  of the lenses of both eyes . Images  will be sent to a 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 18 of 63 central reader for assessment using the LOCS III. C ollection of plasma and saliva cortisol 
sample s will also be conducted.  
The same rater should perform the CGI -S, CGI -I, and MADRS assessments throughout the 
study on a given subject when possible.  
 
Follow -up Period (Day 70 and Day 112)  
Subjects will return to the site for  a follow -up vi sit on Day 70 and Day 112. Study 
procedures/assessments will be conducted, including an ophthalmic exam  and slit lamp 
imaging of the lenses of both eyes . Images  will be sent to a central reader for assessment 
using the LOCS III . Concomitant medications will be reviewed, and AE s recorded.  
Objectives and 
Endpoints:   
Objectives  Endpoints  
Primary  
â€¢ To evaluate the effect of 
treatment with ANC -501 
capsules on depressive symptoms in subjects with 
major depressive disorder 
(MDD)  â€¢ Change from baseline (Day 1) to Day 56  in 
Montgomery- Ã…sberg Depression Rating Scale 
(MADRS) total score  
â€¢ To evaluate the safety and 
tolerability of ANC -501 
capsules in subjects with 
MDD â€¢ Safety  and tolerability as assessed by : 
o Frequency and severity of adverse events  
(AEs) 
o Vital signs  
o Body weight  
o Electrocardiograms (ECGs)  
o Clinical laboratory tests  
o Physical examination  
o Lens Opacities Classification System III 
(LOCS III) 
o Emergent  behavior using Columbia -Suicide 
Severity Rating Scale  (C-SSRS)  
Secondary  
â€¢ To evaluate effect  of 
ANC -501 at all time points 
and percent reduction in total 
symptom score s compared 
with baseline.  â€¢ Change from baseline (Day 1) in the MADRS total score at all time points  
â€¢ Percentage of MADRS responders (â‰¥50% reduction in total score)  
â€¢ Percentage of MADRS remitters (total 
score  â‰¤10) 
â€¢ Change in Hamilton Anxiety Scale (HAM -A) 
total score from Baseline to Da y 56 
â€¢ Change in Clinical Global Impression- Severity 
(CGI -S) score from Baseline to Day 56  
â€¢ Short Form -Health Survey (36 -item)  (SF-36) 
total score and subscale scores from Baseline to 
Day 56 and at all time points  
â€¢ Percentage of Clinical Global Impression -
Improvement (CGI -I) improvers (â€œVery much 
improvedâ€ or â€œMuch improvedâ€)  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 19 of 63 â€¢ Patient Global Impression of Improvement 
(PGI -I) score at Day 56 
â€¢ To assess the PK profile of 
ANC -501 Capsules in 
plasma  using a sparse 
sampling model  â€¢ Plasma concentrations of ANC -501 
  
 
Objectives  Endpoints  
Exploratory  
â€¢ To evaluate changes in 
12-hour urine , plasma , and 
saliva  cortisol â€¢ Changes in 12- hour urine , plasma , and saliva  
cortisol from baseline to Day 56  
â€¢ To evaluate changes in 
biometrics  â€¢ Changes in biometrics using the wearable 
watch -like device  
â€¢ To evaluate biological samples as potential 
biomarkers and metabolites  
â€¢ Patient reported changes in 
Depressi on and Anxiety 
symptoms  â€¢ Baseline levels and/or changes in exploratory 
biomarkers through Day  56 
â€¢ Changes in Hamilton Depression Rating Scale 
(6-item) (HAMD -6) scores from baseline across 
all time points  using ePRO . 
â€¢ Changes in General Anxiety Disorder (7 -item) 
(GAD- 7) from baseline across all time points  
using ePRO . 
  
 
Population:  Inclusion Criteria  
Patients who meet ALL the following inclusion criteria will be eligible to participate in the study:  
1. Demonstrate understanding of the study procedures, restrictions, and willingness to 
participate as evidenced by voluntarily signing and dating the written informed 
consent form.  
2. Adult male or female between 18 and 65 years of age, inclusive.  
3. Good physical health and has no clinically significant findings, as determined by the 
Investigator, on physical examination, 12- lead electrocardiogram  (ECG ), vitals, 
or clinical laboratory tests.  
4. Has no clinically significant findings on  the ophthalmic exam ination  including, Best 
Corrected Visual Acuity  (BCVA) worse than 20/30 or , in the opinion of the 
ophthalmologist  or optometrist , any cataract that may  become clinically significant 
and/or need surgical intervention during the course of the trial.  
5. Able and willing to complete all study requirements.  
6. Diagnos is of current episode of major depressive disorder ( MDD)  at least 8 weeks 
prior to  screening , confirmed by Structured Clinical Interview for DSM -5 â€“ Clinical 
Trials Version  (SCID -5-CT). 
7. Have not responded to their current antidepressant therapy or to dose 
adjustment/treatment changes following a loss of response to their current 
antidep ressant therapy.  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 20 of 63 8. Complete the SAFER  (State vs trait, Assessability, Face and Ecological validity, 
Rule of 3Ps [pervasive, persistent, and pathological]) interview, administered via 
teleconference by a Massachusetts General Hospital ( MGH) psychiatrist or 
psychologist,  and receive a  passing score which confirms a diagnosis of MDD, and 
a minimum Montgomery- Ã…sberg Depression Rating Scale ( MADRS ) total score of 
26. The SAFER interview will also confirm the subjectâ€™s treatment history and 
response to antidepressant therapies ( ADTs ) through the administration of the MGH 
Antidepressant Treatment Response Questionnaire ( ATRQ ). 
9. Receiving a stable dose of the same antidepressant (selective serotonin reuptake 
inhibitor [SSRI], serotonin and norepinephrine reuptake inhibitor [SNRI], 
bupropion or trazodone monotherapy) for the current episode for at least 6 weeks of 
continuous treatment, which can include some or all of the screening period, with 4 
weeks on a stable dose prior to day 1 and has an inadequate response (<50% 
improvement) using the MGH ATRQ.  
10. Willing to maintain stable dose and delay start of other antidepressant or  antianxiety 
medications and any new pharmacotherapy regimens, including benzodiazepine anxiolytics, during the screening and treatment periods.  
11. Has a MADRS total score of â‰¥ 26 at screening and Day 1 (prior to dosing).  
12. Has a 12- hour urine c ortisol level >22.7 nmol/L  (greater than or equal to 8.3 
mcg/L) . 
13. Body 
mass index (BMI) â‰¥18 and â‰¤38 kg/m2 at screening using the formula:  
ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤â„Žð‘¡ð‘¡ (ð‘˜ð‘˜ ð‘¤ð‘¤)â„Žð‘¤ð‘¤ð‘¤ð‘¤ ð‘¤ð‘¤â„Žð‘¡ð‘¡ (ð‘šð‘š)2â„ . 
14. Ag
rees to practice an acceptable method of highly effective birth control at 
screening , throughout study participation, and for 90 days after the last dose of 
study drug. Highly effective methods of birth control include sexual abstinence (for males and females); vasectomy; or a condom with spermicide in combination 
with a highly effective female partnerâ€™s method (for males); and hormonal methods of contraception (i .e., established use of oral, implantable, injectable, or transdermal 
hormones); placement of an intrauterine device; placement of an intrauterine 
system; and mechanical/barrier method of contraception (i .e., condom or occlusive 
cap [diaphragm or cervical/vault cap] in conjunction with spermicide [foam, gel, 
film, cream, or suppository]) (for females).  
Exclusion  Criteria  
Patients who meet any of the following exclusion criteria will be excluded from 
participation in the study:  
1. History of suicide attempt in the past 2 years  or within current MDD episode  
2. Active suicidal ideation with  plan or a  â€œyesâ€ response to items 4 or 5 on the C -SSRS 
in the past 24 months is exclusionary as assessed at Screening and Baseline (Day 1).  
3. Inadequate response to >2  prior ADT s (not including current antidepressant) of at 
least 6 weeks duration each for the episode current at s creening.  
4. Recent history or active clinically significant manifestatio ns of metabolic, hepatic, 
renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, urogenital, neurological, ophthalmic  (especially cataracts) , or ears, 
nose, and throat (ENT) disorders, or any other acute or chronic condition that, in the 
Investigator's opinion, would limit the subject's ability to complete or participate in this clinical study.  
5. Based on  an ophthalm ic examination performed at Screening , patient must not have 
any of the following:  
â€¢ Nuclear opalescence (NO) with a LOCSIII classification > 3.0 in either eye  
â€¢ Nuclear color (NC) with a LOCSIII classification > 3.5 in either eye  
â€¢ Cortical lens opacities (C) with a LOCSIII classification > 2.0 in either eye  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 21 of 63 â€¢ Posterior subcapsular lens opacities (P) with a LOC SIII classification > 0.3 in 
either  
6. History or presence of intellectual disability, pervasive developmental disorder, 
cognitive disorder, neurodegenerative disorder (e.g., Alzheimer â€™s disease, 
Parkinsonâ€™s  disease, multiple sclerosis, Huntington â€™s disease), or brain injury.  
7. Receipt of electroconvulsive therapy (ECT) within 12 months of s creening, 
lifetime receipt of more than one course of ECT , or plans to receive ECT during 
the study.  
8. Receipt of  repetitive  transcranial magnetic stimulation (rTMS) within 12 months 
of screening or planned to receive rTMS during the study.  
9. Plans to initiate or terminate cognitive or behavioral psychotherapy or  alter the 
frequency of ongoing therapy during this study.  
10. Works night shifts or needs to work night shifts during the study.  
11. Females who are pregnant, intend to become pregnant (within 90 days of the last 
dose of ANC -501), are breastfeeding , or have a positive pregnancy test at 
screening or on Day 1 prior to study drug ad ministration.  
12. Known allergy to ANC -501, or related compounds.  
13. Detectable hepatitis B surface antigen (HBsAg), hepatitis C virus antibody 
(HCV  Ab), or human immunodeficiency virus (HIV) antibody at screening.  
14. Active psychosis per Investigator assessment.  
15. Medical history of seizures  (does not include isolated febrile seizures of 
childhood) . 
16. Medical history of bipolar disorder, schizophrenia, and/or schizoaffective 
disorder.  
17. History of alcohol or substance use disorder  in the 12  months prior to screening.  
18. Positive alcohol  breath test . 
19. Positive urine drug screen for hallucinogens, psychoactive inhalants, stimulants, 
opioids, barbiturates, non- prescribed anxiolytics or other non -prescribed sedatives. 
Does not include positive test for cannabinoids , tobacco or caffeine, unless the 
subject meets criteria for substance use disorder for these substances.  
20. Exposure to another investigational medication or device within 30 days or 5  half-
lives (whichever is longer) prior to screening.  
21. Has been previously treated in this study or randomized or tre ated in any other 
study employing ANC -501 (i .e., subject may not have received study drug and 
then re -enrolled).  
22. Administration of drugs to treat  psychiatric or neurologic conditions that have  not 
been taken at a stable dose for at least 4 weeks prior to day 1 . 
23. Need/plan to take moderate to strong inhibitors and/or inducers of 
cytochrome P450 (CYP)3A4 (food, beverages, medications , and 
supplements).  
24. Any condition not identified in the protocol that in the opinion of the Investigator would confound the evaluation and interpretation of the study 
data or may put the subject at risk.  
Dosage Forms and Route of Administration:  50 mg ANC -501 Capsules (5 Ã— 10 mg capsules), administered orally. 
Dose Adjustment for Safety  or 
Tolerability Reasons : During the Open -Label Treatment Period , subjects may receive study drug as long as there 
are no dose -limiting safety/tolerability concerns as determined by the Investigator. Subjects 
who experience moderate or severe AEs while receiving the 50 mg dose of s tudy drug 
which, according to the clinical judgement of the Investigator, are related to study drug, 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0 Confidential  Page 22 of 63 may receive 40 mg for the remainder of the Open -Label Treatment Period  if the AEs are 
intolerable . Subjects who experience moderate or severe related AE s while receiving the 
40 mg dose of study drug might not be able to continue receiving study drug, based on the 
evaluation and clinical judgment of the Investigator, and may be discontinued from further 
treatment.  
Statistical 
Methods : General  
Continuous endpoints will be summarized with n, mean, standard deviation, median, minimum, and maximum. In addition, change from baseline values will be calculated at 
each time point and summarized descriptively. For categorical endpoints, descriptive summ aries will include counts and percentages.  
 
Analysis Populations and Methods  
The Safety Population ( defined as all subjects administered study drug)  will be used to 
provide descriptive summaries of safety data. Treatment -emergent adverse events (TEAEs) 
will be classified by type, incidence, severity, and causality. The overall incidence of AE s 
will be summarized by Medical Dictionary for Regulatory Activities (MedDRA) System 
Organ Class  (SOC)  and Preferred Term  (PT). Data for vital signs, clinical laborator y tests, 
ECG, physical examinations, and concomitant medication usage will also be summarized. 
Out-of-range safety endpoints may be categorized as low or high, where applicable.  
 
Suicidality data collected using the C -SSRS at baseline and at each visit dur ing the active 
Open -Label Treatment Period  will be listed for all subjects. The C -SSRS listings will 
include behavior type and/or category for suicidal ideation and suicidal behavior of the C-SSRS.  
 
Slit lamp imaging performed during the study showing a  change of greater than or equal to 
0.5 on the LOCS III scale  in either eye or  any new incidence of cataract will  be considered 
adverse events and events of special interest.  
 
The Efficacy Population ( defined as all subjects in the Safety Populati on who complete at 
least one day of dosing of study drug and have at least one post -baseline efficacy 
evaluation ) will be used to analyze efficacy data. Efficacy data will be analyzed using 
appropriate descriptive statistics and pre -specified statistical m ethods, as well as other data 
presentation methods where applicable; subject listings will be provided for all efficacy 
data. Efficacy data will be summarized descriptively.  
Sample Size Determination:  Up to 20 subjects will be enrolled.  The sample size was selected based on clinical and not 
statistical considerations.  
 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005 (Version 6.0) 
03 March 2023 Version 6.0  Confidential   Page 23 of 63 1.2. Study Schema  
 

EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential   Page 24 of 63 1.3. Schedule of Events  
Study  Procedure Screening  
Period  Open- Label  Treatment  Period  a Follow -up Period b 
Visit  Days  
Window -30 to -1 Day 1 
c Day 8 
(Â±3 
days) Day 15 
(Â±3 
days)  Day 29 
(Â±3 
days)  Day 43 
(Â±3 
days)  Day 
56/ET 
(Â±3 days)  Day 70 
(Â±3 days)  Day 112 
(Â±3 days)  
Informed consent  X         
Demographics  X         
Medical history  X         
Full physical examination  X      X   
Body weight/height /BMI d X X        
Vitals e X X X    X   
12-lead ECG   X X    X   
Safety l aboratory tests f X X X    X X  
Urine drug and alcohol breath test 
screen  g X X        
Urine pregnancy test h X X        
Hepatitis and HIV serology  X         
Sparse PK blood sampling  i  X X X X X X   
Exploratory biomarker sampling j  X X    X   
Genetic sampling k  X        
Ophthalmic exam and LOCS III l X      X X X 
SCID -5-CT diagnostic interview  X         
MADRS  X X X X X X X X  
HAM -A X X X X X X X X  
CGI-S X X X X X X X X  
C-SSRS  m X X X X X X X X  
HAMD- 6 n     
GAD- 7 n     
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential   Page 25 of 63 Study  Procedure Screening  
Period  Open- Label  Treatment  Period  a Follow -up Period b 
Visit  Days  
Window -30 to - 1 Day 1 
c Day 8 
(Â±3 
days) Day 15 
(Â±3 
days)  Day 29 
(Â±3 
days)  Day 43 
(Â±3 
days)  Day 
56/ET 
(Â±3 days)  Day 70 
(Â±3 days)  Day 112 
(Â±3 days)  
SF-36 n     
EMAW Orienting Questions  n     
CTQ  X         
CGI-I   X X X X X X  
PGI-I   X X X X X X  
SAFER Interview (central rater) o X         
Inclusion/Exclusion Criteria 
Review  X X        
12-hour urine collection for 
cortisol instructions p X      X   
Plasma and saliva cortisol sample 
collection  X      X   
Wearable monitoring instructions  
and Mobile application training  X        
Continuous Wearable monitoring q     
Site download of Wearable data    X X X X X   
ANC -501 dosing r     
ANC -501 Dosing Diary dispensed 
and reviewed  by site      
Dispense study medication   X X X X X    
Adverse  Events s X  
Prior/Concomitant  Medications t X  
Abbreviations: AE  = Adverse Event; BMI = body mass index; CGI -I = Clinical Global Impression -Improvement; CGI -S = Clinical Global Impression -Severity; 
C-SSRS = Columbia -Suicide Severity Rating Scale; CTQ  = Childhood Trauma Questionnaire, 28 -item; ECG  = electrocardiogram; ET  = early  termination; HAM -A = Hamilton 
Anxiety Rating Scale; HIV  = human immunodeficiency  virus; LOCS III= Lens Opacities Classificatio n System III; MADRS  = Montgomery-Ã…sberg Depression Rating Scale; 
MDD = major depressive disorder; MGH ATRQ  = Massachusetts General Hospital Antidepressant Treatment Response Questionnaire; PGI -I = Patient Global Impression of 
Improvement; PK  = pharmacokinetic; SAE = serious adverse event; SAFER  = State vs trait, Assessability, Face and Ecological validity, Rule of 3Ps (pervasive, persistent, and 
pathological); SCID -5-CT = Structured Clinical Interview for DSM -5 â€“ Clinical Trials Version; HAMD -6= Hamilton De pression Rating Scale (6 -item); GAD -7= General 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential   Page 26 of 63 Study  Procedure Screening  
Period  Open- Label  Treatment  Period  a Follow -up Period b 
Visit  Days  
Window -30 to -1 Day 1 
c Day 8 
(Â±3 
days) Day 15  
(Â±3 
days)  Day 29 
(Â±3 
days)  Day 43  
(Â±3 
days)  Day 
56/ET 
(Â±3 days)  Day 70 
(Â±3 days)  Day 11 2 
(Â±3 days)  
Anxiety Disorder (7 -item); SF-36 = Short Form -Health Survey (36 -item).  
 
Schedule of Events (continued)   
Refer to Section  8 for additional details regarding assessments/procedures.  
a. Subjects who discontinue study treatment before completing the study and those who prematurely withdraw from the study for any reason should undergo 
Day 56 visit procedures in- clinic as soon as possible and schedule the Day 70 safety assessments ( at +2 weeks post ET visit)  and Day 112 follow -up 
ophthalmic visit (at +8 weeks post ET visit) . 
b. Subjects will return to the site on Day 7 0 and 112 for a follow -up visit.  
c. Day 1 procedures are to be completed prior to dosing, except for sparse PK sampling which will be performed prior to dosing a nd between 0.75 and 2 hours 
post-dose. 
d. Body weight and height will be measured  at screening and BMI will be calculated. Only body weight and BMI calculation will be performed  at subsequent 
visits.  
e. Vital signs include oral temperature (Â°C), respiratory rate, heart rate, and blood pressure (supine and standing).  
f. Safety laboratory tests will include hematology, serum chemistry, coagulation, and urinalysis. Refer to Table  4 for details.  
g. Urine toxicology for selected drugs of abuse (barbitura tes, amphetamines, cocaine, opioids,) and breath test for alcohol.  
h. Urine pregnancy test will be conducted only in female subjects of childbearing potential. Female subjects who prematurely discontinue will have a  
pregnancy test performed at the ET visit.  
i. A blood sample for sparce PK sampling will be collected pre -dose and between 0.75 and 2 hours post -dose at the Day 1 visit and between 0.75 and 2 hours 
post-dose, whenever possible, at other indicated visits (with the date and time of the previous dose provided by the subject). 
j. A blood sample for exploratory biomarker analysis will be collected in conjunction with PK sampling on Days 1 (pre - post-dose), 8, and 56.  
k. A genetic sample (blood) for exploratory biomarker testing will be collected before the first d ose of drug. 
l. Ophthalmic exam , including slit- lamp imaging,  may be performed by an appropriately trained and qualified individual as delegated by the PI and 
documented in the Study Delegation Log.  However, a licensed ophthalmologist or optometrist must oversee this work and will make the determination on 
subject eligibility as per inclusion criteria #4.   Slit lamp imaging  of the lens of both eyes will be taken and sent to a central reader for assessment using the 
LOCS III. Ideally the exam would be performed after cortisol results are known and the subject is otherwise deemed eligible to continue  with screening 
assessments . Additional slit lamp imaging of the lens of both eyes may be performed during the treatment period  and sent to a central reader for assessment 
using the LOCS III, per Investigator â€™s discretion . 
m. The â€œBaseline/Screeningâ€ C -SSRS form will be completed during screening. The â€œSince Last Visitâ€ C -SSRS form will be completed at any time of day at 
all subsequent time points.  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential   Page 27 of 63 n. The Short Form -Health Survey (36 -item)  (SF-36) weekly .  The Hamilton Depression Rating Scale (6 -item) (HAMD -6) and the General Anxiety Disorder (7 -
item) (GAD -7) will be completed  up to twice a day for a minimum of three days per week  (to achieve 6 collections per week ).  Subjects will answer  EMA 
orienting questions up to three times per  day in conjunction with the other assessments being collected via the EMA application  on their cell phones or the 
provided device.  
o. Conducted by central reader after Screening visit, but prior to Day 1 visit. The MADRS, MGH ATRQ and confirmation of MDD will be conducted by 
central rater for determination of eligibility.  
p. Study site personne l will dispense equipment and train subjects on 12- hour urine collection for measuring cortisol level. At the Day 43 visit, study site 
personne l will dispense equipment and retrain subjects o n the 12- hour urine collection to measure cortisol levels (the collection will be returned to the site at 
the Day  56 visit). On Day 54, the site will contact  the subject to remind them to begin collection on Day 55.  
q. Subjects will wear their wearable watch -like device throughout the day and night except when charging.  
r. At the Day 1 visit, subjects confirmed as eligible will receive a 50 mg dose of study drug at the study site prior to eating.  All other doses will be taken by the 
subjects at home . 
s. All AEs will be recorded from study drug administration on Day 1 until Day 112 visit. Serious adverse events that occur subsequent to the signing of the 
informed consent (i.e., during the Screening Period) as a result of study participation will be recorded, as well as all SAEs  occurring from study drug 
administration on Day 1 until Day 112 visit.  
t. Include s medications  taken within 30 days prior to informed consent and throughout the study.  
 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 28 of 63 2. INTRODUCTION 
2.1. Major Depressive Disorder  
Depression is ranked as the leading cause of disability worldwide by the World Health 
Organization.1 Major depressive disorder (MDD) is a psychiatric disorder that is characterized 
by the occurrence of one or more major depressive episodes, along with an absence of any 
history of manic, mixed, or hypomanic episodes. It is a serious, often recurrent medic al 
condition, which is associated with a 15.9% lifetime risk of suicide attempt.2 Results of the 
World Mental Health Survey Initiative (2011) found that the average lifetime incidence of Diagnostic and Statistical Manual of Mental Disorders, fourth edition ( DSM -IV) major 
depressive episodes was 14.6%, with a 12-month prevalence of 5.5% in higher income counties .
3 
Similarly, the National Comorbidity Survey -Replication4 found the incidence of depression to be 
6.6% over 12-months, with a 16.2% lifetime incidence. In addition to the high mortality rate due 
to suicide, depressed patients are more likely to develop coronary artery disease and type 2 diabetes.
5 
Current treatments available for depression include psychotherapy (for mild depression), antidepressant medications, a combination of medication and psychotherapy (for mild- to-
moderate depression), and electroconvulsive therapy (moderate- to-severe depression). Despite 
the availability of numerous antidepressant drugs (e.g., monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors [SSRIs], serotonin norepinephrine reuptake inhibitors [SNRIs]), there remains an unmet need for the pharmacological treatment of 
MDD. With currently available medications, alleviation of depressive symptoms is often not 
observed until several weeks of treatment have been received. Even after an adequate duration of treatment, the most commonly used treatments today (e.g., SSRIs and SNRIs) only result in 
approximately 35% to 45% of patients achieving clinical remission.
6 Approximately 30% of 
patients are resistant to a series of treatments according to STAR*D (Sequenced Treatment 
Alternatives to Relieve Depression) stud y.7 Moreover, side effects are still a concern, even with 
newer medications. Thus, there is a clear need for efficacious and well -tolerated agents that can 
effectively treat depression and prevent recurrent episodes of depression. 
Stress has also been hypothesized to be a pivotal factor in the pathophysiology of depression, 
specifically by way of the hypothalamus- pituitary -adrenal (HPA) axis, which appears to be 
a prominent mechanism by which the brain reacts to both acute and chronic stress through 
feedback loops involving several neuroendocrine hormones, including adrenocorticotropic 
hormone (ACTH) and cortisol. In addition, both corticotropin- releasing factor (CRF) 
and arginine vasopressin (AVP), both of which are produced in the paraventricular nucleus of the 
hypothalamus8,9 are considered pri mary factors in the regulation of HPA axis activity. Receptor 
subtypes for these neuropeptides, which may be involved in the regulation of HPA axis activity, 
have attracted much attention as potential targets for the treatment of depression and anxiety. 
ANC-501 is an investigational new drug with antagonistic activity of the vasopressin receptor 1b 
(V1b receptor), which plays a role in the modulation of stress and mood. Based on nonclinical 
studies conducted, ANC-501 appears to be a promising candidate for clinical development with 
a novel mode of action that may benefit MDD patients. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 29 of 63 2.2. Mechanism of Action of Vasopressin Receptor 1b (V1b Receptor)  
Arginine vasopressin, a cyclic nonapeptide, together with CRF, are principal factors in the 
regulation of ACTH release from the anterior pituitary ,8 and have been reported to play an 
important role in mood regulation. Arginine vasopressin is synthesized in the parvocellular 
division of the paraventricular nucleus of the hypothalamus, which is linked to activation of the 
HPA axis, and upon stress exposure, AVP is released from the median eminence into the 
pituitary portal circulation, where it strongly potentiates the effects of CRF on the release of ACTH. Clinically, the plasma AVP levels are elevated in patients with major depression, 
compared with healthy controls.
10,11 In previous studies, subjects with melancholic-type or 
anxious-retarded depression exhibited elevated plasma AVP levels. Plasma AVP levels are also 
reportedly positively correlated with cortisol levels during depression, particularly in suicide 
victims .12 Moreover, the quantities of AVP-immunoreactive neurons and AVP messenger RNA 
(mRNA) in the paraventricular nucleus are increased during depression,13,14 particularly in 
subjects in the melancholic subgroup,13 and pituitary AVP responsibility in the regulation of the 
HPA axis is increased.15 The involvement of the AVP system in anxiety disorders has also been 
suggested. 
AVP exerts its effects via three receptor subtypes: V 1a, V1b, and V 2. These subtypes are G -protein 
coupled receptors.16 Among them, the V 1b receptor is mainly expressed  in the anterior pituitary 
and is thought to be involved in the regulation of HPA axis activity and emotional processes.17 
Indeed, SSR149415, a non-peptide V 1b receptor antagonist with high affinity and potent 
antagonistic activity for the V 1b receptor ,18 has been reported to attenuate increases in 
plasma  ACTH induced by corticotropin-releasing hormone ( CRH )+AVP ,19 and to exhibit 
antidepressant - and anxiolytic- like activities in a  variety of rodent models of depression 
and anxiet y, with more pronounced effects in models involving stressful situations .18,19,20 
Therefore, blockade of V 1b receptor may provide a novel approach to treating stress- related 
disorders such as depression and anxiety disorders. 
ANC -501 is a potent and selective antagonist of V 1b receptor in both in vitro and in vivo studies 
and has been shown to possess antidepressant activity in several animal models of depression, 
including one which mimics severely impaired HPA axis function. 
2.3. Rationale for Targeting V1b Receptor in Treatment of Depression  
A series of in vitro studies was conducted to define  the affinity of ANC-501 to the V 1b receptor, 
as well as a battery of in vivo studies to characterize the efficacy profile in MDD and its 
anxiolytic- like potential in animal models.  
During in vivo rat studies, the immobility time in the forced swimming tes t and the 
hyperemotionality in a rat olfactory bulbectomy model, both of which are indicative of depressive states, were each significantly reduced by treatment with ANC -501. In the olfactory 
bulbectomy model, ANC-501 exhibited efficacy following chronic treatment for 14 days, as did 
fluvoxamine. In addition, ANC-501 significantly improved depressive-like behavior induced by 
repeated corticosterone injection, a depression model which has been reported to be resistant to fluvoxamine and imipramine ,
21 indicating that ANC -501 may be effective for patients with 
severely impaired HPA axis function. In an anxiety model (social interaction behavior in rats), ANC -501 demonstrated anxiolytic activity as well. This preclinical evidence further suggests 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 30 of 63 that a V 1b receptor antagonist may be useful in the treatment of MDD with co-morbid anxiety 
disorders. 
2.3.1. Evaluation in Humans  
Three Phase 1 studies (a single ascending dose [SAD] study [TS121-US101], a multiple 
ascending dose [MAD] study [TS121-US102], and a PET receptor occupancy study 
[TS121-US103]) and one Phase 2 study (TS121-US201) have been conducted in the Unit ed 
States .  
Pharmacokinetic (PK) studies indicate that f ollowing single and multiple oral administration of 
ANC -501, increases in plasma ANC-501 peak and total exposures ( maximum plasma 
concentration [C max] and area under the concentration- time curves [ AUCs ]) were observed with 
increases in dose. ANC -501 reached C max within 4 hours after dosing and declined with apparent 
half-life ( tÂ½) of approximately 20 hours. No food effect was observed on AUCs of ANC-501, 
while C max was red uced under fed conditions. In the MAD study, the plasma trough 
concentrations of ANC-501 appeared to reach steady state by 5 days after dosing and the exposures accumulated to approximately 2 times. Low renal clearance (CL
r) suggested minimal 
contribution of the urinary excretion of ANC-501. Though two metabolites (M5 and M9) were 
found in plasma, the unchanged form was proposed as a predominant component. In addition, 
PET study revealed the relationship between plasma exposure of ANC-501 and V 1b receptor 
occupancy in the pituitary. 
Overall, 78 healthy and 32 adult subjects with MDD were administered ANC -501 to date. In the 
Phase 2 study, there was no statistically significant difference observed in the primary endpoint 
(Montgomery-Ã…sberg Depression Rating S cale [MADRS] Change from Baseline to Week 
6positive trends were observed for the scores of depression scales in ANC-501 treated groups 
(10 mg and 50 mg) versus placebo. The lack of statistical significance may be attributable to the 
small number of subjects enrolled. 
Safety Findings in Clinical Studies  
A top dose of 50 mg for 6 weeks  was deemed safe and well tolerated. There were no deaths or 
serious adverse events ( SAEs ) reported in any of the studies. No safety trends were observed in 
clinical laboratory,  electrocardiogram ( ECG ), vital signs, physical examinations, or cardiac 
telemetry. In consideration of the nonclinical findings at the time of the MAD study, comprehensive eye examinations were performed. In Phase 2a study, eye examinations with a standardized lens opacity grading scale (Lens Opacities Classification System III [LOCS III]), 
were conducted to evaluate this risk in the study. Increase from baseline in the LOCS III grade of 
â‰¥0.5 (Nuclear Opalescence [NO]), â‰¥0.8 (Cortical) or â‰¥0.5 (Posterior S ubcapsular), or changes 
considered to be clinically significant as per the ophthalmologist or optometrist , were defined in 
the protocol as events of clinical significance. Two events of lenticular opacities were reported in Phase 2a study TS121-US201 in patients dosed with ANC-501 in the 50 mg dose group. One of 2 patients had an increase of NO score from baseline at Visit 6 in the left and right eye of 0.9 and 
0.8 points, respectively, which was reportable as an event of clinical significance per protocol. 
Per the Investigator, the difference from the initial LOCS III assessment did not reflect actual 
change in lens opacity but rather intra-observer variability. The I nvestigator rated the event as 
mild in intensity and considered it to be not related to the study drug. The second patient had an increase of NO score from baseline at visit 6 in the unilateral (right) eye of 0.7 points, which was 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 31 of 63 reportable as an event of clinical significance per protocol. The Investigator rated this event as 
mild in intensity and considered it to be possibly related to the study drug. The nonclinical 
studies demonstrated changes in the lens in a select number of study animals that were noted either in the posterior pole of the lens or affecting cortical lens f ibers. In the clinical program, 
neither of the 2 patients with reports of progression of NO that met the level of clinical significance according to the study protocol were noted to have posterior polar or cortical changes. Further, the LOCS III scoring ha s a standardized range for NO from 1 â€“6, with 1 being 
the lowest standard image available for comparison. The scores reported for one  patient were 0.3 
at baseline and increasing to 1.0 at the time of the event. The initial score is below the level of the fi rst comparative image on the LOCS scale template, and thus inter -visit variability could 
account for the noted difference. The second patient had changes noted in both eyes, with 0.7 and 0.6 noted at baseline in the right and left eye, respectively and 1.5 noted at the time of the reported event in both eyes. Given the relative subjective nature of lens grading, and the fact that 
at initial examination the scoring was below the lowest standard image standard, intra -grader 
variability likely accounted for these changes, as noted by the Investigator for the second patient. 
In the Phase 2 study, there was no statistically significant difference observed in the primary endpoint ( Montgomery- Ã…sberg Depression Rating Scale [ MADRS ] Change from Baseline to 
Week 6), although positive trends were observed for the scores of depression scales in ANC -501 
treated groups (10 mg and 50 mg) versus placebo. The lack of statistical significance may be 
attributable to the small number of subjects enrolled.  
In conclusion, these re sults suggest that ANC -501 (ANC -501) may be useful for the treatment of 
patients with MDD.  
2.4. Risk/Benefit  
Three Phase 1 studies, a SAD study (TS121- US101), a MAD study (TS121- US102) and a PET 
receptor occupancy study (TS121- US103), and one Phase 2 study in M DD (TS121 -US201) have 
been conducted in the US. Overall, 78 healthy male and female adult subjects and 32 adult 
subjects with MDD were administered ANC -501 to date. A top dose of 50 mg for 6 weeks was 
deemed safe and well -tolerated. There were no deaths or  SAEs reported in any of the studies. All 
events across trials were either mild or moderate in intensity. Moreover, no safety trends were observed in clinical laboratory, ECG, vital signs, physical examinations, or cardiac telemetry. 
In consideration of th e nonclinical findings (rat) at the time of the MAD study, comprehensive 
prospective slit lamp examinations were performed in the P hase 2 trial. Two events of lenticular 
opacity were reported as clinically significant by prespecified criteria on the LOC S III rating 
scale in 2 subjects (1 event each) in the 50 mg group. These events were rated as mild i n 
intensity , were not accompanied by any changes in vision, and did not require treatment. One 
was judged as â€œpossibly relatedâ€ and the other was judged as â€œnot relatedâ€ to ANC 501. While Study TS121- US201 was not enrolled to completion, patients treated with ANC -501 in 
combination with their underlying antidepressant showed numerical improvement compared to 
placebo. Consistent with the hypothesized mechanism of action of ANC -501, those patients with 
elevated baseline 12 -hour urine cortisol concentration showed substantially larger separation 
from placebo at the end of 6 weeks in both dose groups tested. In the case of the high cortisol 
50 mg sub- group, these di fferences continued to increase throughout the follow -up period.  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 32 of 63 Approximately 30% of patients are resistant to a series of treatments according to the STAR*D 
study. There is little data -driven guidance on next steps to treat MDD patients in the event of a  
first-line failure. Importantly, side effects are a major concern for patients particularly the use of 
antipsychotic agents as adjunctive therapies and those used to treat treatment -resistant depression 
(TRD). Thus, there is a clear need for new, efficaci ous, well -tolerated agents to both treat 
depression episodes and prevent recurrent episodes of depression.  
The safety profile of ANC -501, based o n the previously conducted trials and preliminary clinical 
data, suggest that ANC -501 may also be well  tolerate d in patients and efficacious as an 
adjunctive treatment in select MDD patients. The current significant unmet need in the treatment 
of depression, remaining as a number one cause of disability worldwide, justifies a favorable risk-benefit ratio, and inves tigation of ANC -501 in MDD. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 33 of 63 3. OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary  
â€¢ To evaluate the effect of treatment with 
ANC -501 capsules on depressive 
symptoms in subjects with major 
depressive disorder (MDD)  â€¢ Change from baseline (Day 1) to Day 56 in Montgomery- Ã…sberg 
Depression Rating Scale (MADRS) total score  
â€¢ To evaluate the safety and tolerability 
of ANC -501 capsules in subjects with 
MDD â€¢ Safety and tolerability as assessed by:  
o Frequency and severity of adverse events  (AEs) 
o Vital signs  
o Body weight  
o Electrocardiograms (ECGs) 
o Clinical laboratory tests  
o Physical examination  
o Lens Opacities Classification System III (LOCS III)  
o Emergent Suicidal behavior using Columbia -Suicide Severity 
Rating Scale (C -SSRS)  
Secondary  
â€¢ To evaluate effect  of ANC -501 at all 
time points and percent reduction in 
total symptom scores  compared with 
baseline.  â€¢ Change from baseline (Day 1) in the MADRS total score at all 
time points  
â€¢ Percentage of MADRS responders (â‰¥50% reduction in total score)  
â€¢ Percentage of MADRS remitters (total score â‰¤10)  
â€¢ Change in Hamilton Anxiety Scale (HAM -A) total score from 
Baseline to Day 56  
â€¢ Change in Clinical Global Impression- Severity (CGI -S) score 
from Baseline to Day 56  
â€¢ Short Form -Health Survey (36 -item) (SF -36) total score and 
subscale scores  from Baseline to Day  56 and at all time points  
â€¢ Percentage of Clinical Global Impression -Improvement (CGI- I) 
improvers (â€œVery much improvedâ€ or â€œMuch improvedâ€)  
â€¢ Patient Global Impression of Improvement (PGI -I) score at 
Day 56 
â€¢ To assess the pharmacokinetic ( PK) 
profile of ANC -501 Capsules in plasma 
using a sparse sampling model  â€¢ Plasma concentrations of ANC -501  
Exploratory  
â€¢ To evaluate changes in 12-hour urine, 
plasma, and saliva cortisol  â€¢ Changes in 12- hour urine, plasma, and saliva cortisol from 
baseline to Day 56  
â€¢ To evaluate changes in biometrics  â€¢ Changes in biometrics using the wearable watch -like device  
â€¢ To evaluate biological samples as potential biomarkers and metabolites  
â€¢ Patient reported changes in Depression 
and Anxiety symptoms  â€¢ Baseline levels and/or changes in exploratory biomarkers through 
Day 56 
â€¢ Changes in Hamilton Depression Rating Scale (6- item) (HAMD -
6) scores from baseline across all time points  using eP RO 
â€¢ Changes in General Anxiety Disorder (7- item) (GAD -7) from 
baseline across all time points  using ePRO  
  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 34 of 63 4. STUDY DESIGN  
4.1. Overall Design  
This is a single -arm, open-label Phase 2 study to assess the safety, tolerability, pharmacokinetics 
(PK), and efficacy of ANC -501 oral capsules as adjunctive treatment in subjects diagnosed with 
major depressive disorder (MDD).  
With the exception of subjects permitted to use current stable antidepressant treatment, initiation 
of psychotropic medications and other medications that may potentially have an impact on 
efficacy or safety endpoints will not be allowed between screening and completion of the Day 56 
assessments. Psychotropic medications, which must have been initiated at least 8 weeks  prior to 
screening, must remain at a stable dose until completion of the Day 56 assessments. During the 
study, efficacy and safety assessments will be performed and blood samples collected for PK 
analysis of ANC-501and future exploratory biomarker and gene tic analysis . A wearable 
watch -like device will collect data on biometrics, which may be used for exploratory analyses. 
Subjects will receive 50 mg ANC -501 Capsules (5 Ã— 10 mg capsules) orally once daily at least 
1 hour prior to the morning meal for 8 weeks beginning with the first dose administered in the clinic on Day 1, and will return to the clinic for scheduled visits on Days 8, 15, 29, 43, and 56. 
Follow-up visits will occur on Day 70 and 112. All visits after Day 1 allow a visit window of Â±3 
days. 
Total duration of participation is 20 weeks (up to 30 days screening, 8 weeks dosing, 8 weeks 
follow-up). 
The following is an overview of study procedures/assessments (refer to the Schedule of Events 
[Section  1.3] for specific procedures/assessments and  their timing, with further details located in 
Section  8): 
Screening Period (Day -30 to Day -1) 
After providing informed consent, eligibility assessments will include review of demographics, 
medical histor y, prior/concomitant medications, full physical examination, vital sign 
assessments, body weight/height/body mass index ( BMI ) measurements, urine pregnancy test 
(for female subjects of childbearing potential), urine drug and alcohol breath test screen, safety laboratory tests (i.e., hematology, serum chemistry, coagulation, and urinalysis), hepatitis and 
human immunodeficiency virus (HIV) screen, and plasma and saliva cortisol sample collection . 
The Structured Clinical Interview for DSM -5 â€“ Clinical Trials Version  (SCID -5-CT) will be 
employed for the determination of MDD and will be performed by a qualified, trained, validated healthcare professional.  
Qualified staff will also complete the Montgomery -Ã…sberg Depression Rating Scale (MADRS), 
Hamilton Anxiety R ating Scale (HAM -A), Clinical Global Impression -Severity (CGI- S), 
Columbia- Suicide Severity Rating Scale (C -SSRS), and Childhood Trauma Questionnaire 
(CTQ).  
Ophthalmic exams , including slit- lamp imaging,  may be performed by an appropriately trained 
and qualified  individual as delegated by the PI and documented in the Study Delegation Log. 
However, a licensed ophthalmologist or optometrist must oversee this work and will make the 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 35 of 63 determination on subject eligibility as per inclusion criteria #4.   Slit lamp imaging of the lens of 
both eyes will be taken and sent to a central reader for assessment using the LOCS III 
classification . 
Study site personne l will dispense equipment for 12 -hour urine collection to measure cortisol 
levels.  
A call between the subject  and the qualified  central rater will be scheduled to allow the rater  to 
administer the Massachusetts General Hospital Antidepressant Treatment Response 
Questionnaire (MGH ATRQ) for assessment of current antidepressant therapy (ADT), adequacy 
of duration a nd dose of prior and current ADT, as well as degree of improvement, to ensure only 
patients with inadequate response (<50% improvement) are included. The central rater will also 
complete the MADRS assessment and SAFER inventory (State vs trait, Assessability, Face 
and Ecological validity, Rule of 3Ps  [pervasive, persistent, and pathological] ) for confirmation of 
eligibility (diagnosis, severity, and treatment history). Results will be communicated to the site prior to Day 1.  
No changes to medication s are allowed during the screening period, and screening can be less 
than 30 days if all other criteria are met .
 
Open -Label Treatment  Period  (Days 1, 8, 15, 29, 43, 56)  
At the Day 1 visit only, s ubjects confirmed as eligible will receive a 50 mg dose of study drug 
prior to eating. Subjects who cannot tolerate 50 mg will receive 40 mg for the remainder of the study. Subjects who cannot tolerate 40 mg will be terminated from the study. Before releasing subjects, study site personnel will dispense and train subjects on a  dosing diary, the wearable 
watch -like device and  mobile application. ANC -501 will be dispensed to subjects with 
instructions to take the medication every morning at least 1 hour prior to eating breakfast.  
During visits, safety procedures/assessments and administration of assessments/scales (including 
from Day 8 onward, the Clinical Global Impression- Improvement [CGI -I] and the Patient Global 
Impression of Improvement [PGI -I]) will be conducted. During specific visits, PK blood samples 
will be collected, as well as blood samples for future exploratory biomarker and genetic analysis. Concomitant medications and dosing diary will be reviewed, the dosing diary will be returned to 
the subject, and adverse events (AEs) recorded. At all visits after Day 1, recording/accounting 
for any returned/unused ANC -501 will be performed and ANC -501 will be dispensed to subjects 
with a reminder to take the medication every morning at least 1 hour prior to eating breakfast.  
At home activities  
Subjects  will take study medication every morning (at least 1 hour prior to eating breakfast) , 
make entries into  the dosing diary, and wear their wearable watch -like device throughout the 
day and night except when charging. Subjects will also complete  EMA orientin g questions , 
the Hamilton Depression Rating Scale (6 -item) (HAMD -6) and the General Anxiety Disorder 
(7-item) (GAD -7) twice a day for three days per week, and the Short Form -Health Survey 
(36-item) (SF -36) weekly
 in the EMA Wellness smartphone/tablet application . 
At the Day 43 visit, study site personnel will dispense equipment and retrain subjects on the 
12-hour urine collection to measure cortisol levels (the collection will be returned to the site at 
the Day  56 visit). On Day 54, the site will contact  the subject to remind them to begin collection 
on Day 55.  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 36 of 63 At the Day 56 visit, s ubjects will take their last study medication and visit the site to return their  
12-hour urine collection, all remaining medication , the dosing diary, and wearable watches. 
Study procedures/assessments will be conducted, including an ophthalmic exam and  slit lamp 
imaging of the lenses of both eyes . Images  will be sent to a central reader for assessment using 
the LOCS III. Collection of plasma and saliva cortisol samples will also be conducted.   
The same rater should perform the CGI-S, CGI-I, and MADRS assessments throughout the study 
on a given subject when possible. 
Follow-up Period (Day 70 and Day 112) 
Subjects will return to the site for a follow-up visit on Day 70 and Day 112. Study 
procedures/assessments will be conducted, including an ophthalmic exam and slit lamp imaging 
of the lenses of both eyes. Images  will be sent to a central reader for assessment using the LOCS 
III. Concomitant medications will be reviewed, and Ae s reco rded. 
4.2. Justification for Dose  
ANC -501 dose selection was based on accumulated experience from preclinical studies 
and previous clinical trials. The SAD study (TS121-US101) and MAD study (TS121-US102) 
provide safety and tolerability support for the current doses. A PET receptor occupancy study 
(TS121-US103) provides rationale for doses of 10 mg and 50 mg orally once daily. From results 
of the PET receptor occupancy study, 10 mg and 50 mg doses were modeled to provide 
approximately 55% and 75% receptor occupancy, respectively. In the Phase 2 study (TS121-US201), the 50 mg dose suggested efficacy in the sub-population of subjects with higher cortisol levels.  
4.3. End of Study Definition  
End of study is defined as the date when  the last subject has completed  the final  scheduled 
procedure shown in the Schedule of Events  (Section  1.3). 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 37 of 63 5. STUDY POPULATION  
Subject eligibility must be verified prior to e nrollment. Prospective approval of protocol 
deviations to recruitment and enrollment criteria (also known as protocol waivers or exemptions) 
is not permitted.  
5.1. Inclusion Criteria  
Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 
1. Demonstrate understanding of the study procedures, restrictions, and willingness to participate as evidenced by voluntarily signing and dating the written informed consent form.  
2. Adult male or female between 18 and 65 years of age, inclusive. 
3. Good physical health and has no clinically significant findings, as determined by the Investigator, on physical examination, 12- lead electrocardiogram (ECG), vitals, 
or clinical laboratory tests.  
4. Has no clinically significant findings on the opht halmic examination , including Best 
Corrected Visual Acuity (BCVA) worse than 20/30 or, in the opinion of the 
ophthalmologist or optometrist, any cataract that may become clinically significant 
and/or need surgical intervention during the course of the tria l. 
5. Able and willing to complete all study requirements. 
6. Diagnosis of current episode of major depressive disorder (MDD) at least 8 weeks prior 
to screening  confirmed by  Structured Clinical Interview for DSM -5 â€“ Clinical Trials 
Version  (SCID -5-CT). 
7. Have not responded to their current antidepressant therapy or to dose adjustment/treatment changes following a loss of response to their current antidepressant therapy. 
8. Complete the SAFER interview, administered via teleconference by a Massachusetts General Hos pital (MGH) psychiatrist or psychologist, and receive a passing score which 
confirms a diagnosis of MDD, and a minimum Montgomery-Ã…sberg Depression Rating 
Scale (MADRS) total score of 26. The SAFER interview will also confirm the subjectâ€™s 
treatment histor y and response to antidepressant therapies (ADTs) through the 
administration of the MGH Antidepressant Treatment Response Questionnaire (ATRQ). 
9.  Receiving a stable dose of the same antidepressant (selective serotonin reuptake inhibitor 
[SSRI], serotonin and norepinephrine reuptake inhibitor [SNRI], bupropion or trazodone 
monotherapy) for the current episode for at least 6 weeks of continuous treatment, which 
can include some or all of the screening period, with 4 weeks on a stable dose prior to 
day 1 and has an inadequate response (<50% improvement) using the MGH ATRQ.  
10. Willing to maintain stable dose and delay start of other antidepressant or antianxiety medications and any new pharmacotherapy regimens, including benzodiazepine anxiolytics, during the screening and treatment periods. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 38 of 63 11. Has a MADRS total score of â‰¥ 26 at screening and Day 1 (prior to dosing).  
12. Has a 12- hour urine cortisol level >22.7 nmol/L  (greater t han or equal to 8.3 mcg/L) . 
13. Body mass index (BMI) â‰¥18 and â‰¤38 kg/m2 at screening using the formula : 
ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤â„Žð‘¡ð‘¡ (ð‘˜ð‘˜ð‘¤ð‘¤)â„Žð‘¤ð‘¤ð‘¤ð‘¤ð‘¤ð‘¤â„Žð‘¡ð‘¡ (ð‘šð‘š)2â„ . 
14. Agrees to practice an acceptable method of highly effective birth control at screening, 
throughout study participation, and for 90 days after the last dose of study drug. Highly effective methods of birth control include sexual abstinence (for males and females); 
vasectomy; or a condom with spermicide in combination with a highly effective female 
partnerâ€™s method (for males); and hormonal methods of contraception (i.e., established use of oral, implantable, injectable, or transdermal hormones); placement of an 
intrauterine device; placement of an intrauterine system; and mechanical/barrier method 
of contraception (i.e., condom or occlusive cap [diaphragm or cervical/vault cap] in conjunction with spermicide [foam, gel, film, cream, or suppository]) (for females).  
5.2. Exclusion Criteria  
Patients who meet any of the following exclusion criteria will be excluded from participation in the study:  
1. History of suicide attempt in the past 2 years  or within current MDD epi sode. 
2. Active suicidal ideation with plan or a  â€œyesâ€ response to items 4 or 5 on the C -SSRS in 
the past 24 months is exclusionary as assessed at Screening and Baseline (Day 1).  
3. Inadequate response to >2  prior ADTs (not including current antidepressant) of a t least 
6 weeks duration each for the episode current at screening.  
4. Recent history or active clinically significant manifestations of metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, 
dermatological, ur ogenital, neurological, ophthalmic  (especially cataracts) , or ears, nose, 
and throat (ENT) disorders, or any other acute or chronic condition that, in the 
Investigator's opinion, would limit the subject's ability to complete or participate in this clinical  study. 
5. Based on an ophthalm ic examination performed at Screening , patient must not have any 
of the following:  
â€¢ Nuclear opalescence (NO) with a LOCSIII classification > 3.0 in either eye 
â€¢ Nuclear color (NC) with a LOCSIII classification > 3.5 in either eye  
â€¢ Cortical lens opacities (C) with a LOCSIII classification > 2.0 in either eye  
â€¢ Posterior subcapsular lens opacities (P) with a LOCSIII classification > 0.3 in either  
6. History or presence of intellectual disability, pervasive developmental disorder, cognitive 
disorder, neurodegenerative disorder (e.g., Alzheimerâ€™s disease, Parkinsonâ€™s disease, 
multiple sclerosis, Huntingtonâ€™s disease), or brain injury. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 39 of 63 7. Receipt of electroconvulsive therapy (ECT) within 12 months of screening, lifetime 
receipt of more than one co urse of ECT, or plans to receive ECT during the study. 
8. Receipt of repetitive transcranial magnetic stimulation (rTMS) within 12 months of screening or planned to receive rTMS during the study. 
9. Plans to initiate or terminate cognitive or behavioral psychotherapy or alter the frequency of ongoing therapy during this study. 
10. Works night shifts or needs to work night shifts during the study. 
11. Females who are pregnant, intend to become pregnant (within 90 days of the last dose of ANC -501), are breastfeeding, or have a positive pregnancy test at screening or on Day 1 
prior to study drug administration. 
12. Known allergy to ANC-501, or related compounds. 
13. Detectable hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV) antibody at screening. 
14. Active psychosis per Investigator assessment. 
15. Medical history of seizures  (does not include isolated febrile seizures of childhood).  
16. Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder. 
17. History of alcohol or substance use disorder  in the 12 months prior to screening. 
18. Positive alcohol breath test . 
19. Positive urine drug screen for hallucinogens, psychoactive inhalants, stimulants, opioids, 
barbiturates, non-prescribed anxiolytics or other non- prescribed sedatives. Does not 
include positive test for cannabinoids , tobacco  or caffeine, unless the subject meets 
criteria for substance use disorder for these substances.  
20. Exposure to another investigational medication or device within 30 days or 5  half-lives 
(whichever is longer) prior to screening. 
21. Has been previously treated i n this study or randomized or treated in any other study 
employing ANC501  (i.e., subject may not have received study drug and then reenrolled).  
22. Administration of drugs to treat  psychiatric or neurologic conditions that have not be en 
taken at a stable dose for at least 4 weeks prior to day 1. 
23. Need/plan to take moderate to strong inhibitors and/or inducers of cytochrome P450 
(CYP)3A4 (food, beverages, medications, and supplements). 
24. Any condition not identified in the protocol that in the opinion of the Investigator would confound the evaluation and interpretation of the study data or may put the subject at risk. 
5.3. Subject Enrollment  
Subject eligibility must be verified prior to enrollment. Upon eligibility verification, subject  
information will be entered into an Interactive Response Technology (IRT) system. The first 
dose of study drug should be administered within 72 hours (all efforts should be made to initiate 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 40 of 63 treatment as soon as possible after registration)  following entry into the IRT . The  date the first 
dose of study drug is administered is the date the subject is considered enrolled into the study.  
5.4. Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical study but not 
subsequently enrolled in the study. A minimal  set of screen failure information is required to 
ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, 
and any serious adverse e vent (SAE) that occurs after completion of the informed consent form 
(ICF).  
Subjects who do not meet the criteria for participation in this study (i.e., screen failures) may be rescreened after discussion with the Medical Monitor. Previously completed study assessments 
remaining within the protocol -defined window will be accepted for rescreening. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 41 of 63 6. STUDY TREATMENT  
6.1. Study Treatmen t Administered  
Subjects will receive 50 mg ANC -501 Capsules (5 Ã—  10 mg capsules) orally once daily at least 
1 hour prior to the morni ng meal  for 8 weeks beginning with the first dose administered in the 
clinic on Day  1. 
6.2. Handling, Storage , and Accountability  
ANC -501 Capsules are stored in child- resistant 35 -count bottles  at controlled room temperature 
(15â€“25Â°C/ 59â€“77Â°F).  
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study drug received, and any discrepancies are reported and 
resolved before use of the study drug. 
Only subjects enrolled in the study may receive study drug, which may only be supplied or 
administered by authorized site staff. All study drug must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions, with access limited to the Investigator and authorized site staff.  
The Investigator is responsible for study drug accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records). The Investigator or designee will mainta in a record of all study drug received and dispensed.  
Further guidance and information for the final disposition of unused study drug are provided in the Pharmacy Manual.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
Not applicable; this is an open- label study.  
6.4. Treatment Compliance  
Drug accountability will be performed by the study site using appropriate source documentation and recorded in the eCRF.  
 
6.5. Dose Modifications  
During the Open -Label Treatment Period , subjects will be able to receive study drug as long as 
there are no dose -limiting safety/tolerability concerns as determined by the Investigator. Subjects 
who experience moderate or severe AEs  while receiving the 50 mg dose of study drug which, 
according  to the clinical judgement of the Investigator, are related to study drug, may receive 
40 mg for the remainder of the Open -Label Treatment Period  if the AE s are intolerable. Subjects 
who experience moderate or severe related AE s while receiving the 40 mg dose of study drug 
might not be able to continue receiving study drug based on the evaluation and clinical judgment of the Investigator and may be discontinued from further treatment.  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 42 of 63 6.6. Continued Access to Study Drug after the End of Study  
There are currently  no plans to provide ANC -501 to subjects after the study ends . 
6.7. Treatment of Overdose  
No information regarding overdose of ANC -501 in humans is available. The subject should be 
closely monitored for signs of toxicity, and the Medical Monitor notified immedi ately. T here is 
no specific antidote for  overdose  of ANC -501, and general  supportive  care  should be  provided.  
6.8. Concomitant Medications and Therapies  
Any medication or vaccine (s) (including over -the-counter  or prescription medicines, recreational 
drugs, vitamins, and/or herbal supplements) that the subject received within 30 days prior to 
informed consent  or receives during the study must be recorded along with the reason for use, 
start and end dates, dose, and frequency. The Medical Monitor should be contacted if there are any questions regarding prior or concomitant therapy. 
Subjects may not have received another investigational medication or device within 30 days 
prior to screening. Psychotropic medications, which must have been initiated at least 8 weeks  
prior to screening, must remain at a stable dose until completion of the Day 56 assessments . 
Strong inhibitors and/or inducers of CYP3A4 (food, beverages, medications, and supplements) are not permitted . 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 43 of 63 7. DISCONTINUATION OF STUDY TREATMENT AND SUBJECT 
WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
A subject must be discontinued from study treatment for any of the following:  
1. Unacceptable toxicity, despite maximal supportive care and/or dose reduction. 
2. Subjects  exhibiting a c hange in the LOCS III greater than or equal to 0.5 i n Nuclear 
Opalescence, Cortical Opalescence or Posterior Subcapsular Opalescence i n either eye or  
clinically significant eye changes (e.g., incident of cataract) . 
3. Investigator  decision  (may include  the need for  antidepress ant therapy  or other therapy  
not otherwise permitted in the study, including ECT or changes to cognitive/behavioral 
psychotherapy ) or noncompliance with study requirements . 
4. Subject becomes  or intends to become pregnant . 
5. Subject w ithdrawal of consent for further study treatment. 
6. Study terminat ion by the Sponsor . 
Subjects discontinuing treatment should complete the Early Termination visit procedures and enter the Follow -up Period. 
7.2. Subject Withdrawal from Study  
A subject will be withdrawn from all study participation  (i.e., discontinued without further 
follow -up): 
1. Withdrawal of consent to further follow -up assessments, irrespective of the reason  
2. Lost to follow -up 
a. A subject will be considered lost to follow -up after  repeated fail ure to attend 
scheduled study visits , and who is unable to be contacted by the study site. Only 
after 3  phone calls (if possible)  are attempted  and no response received from a 
certified letter (or equivalent local method) to the subjectâ€™s last known mailing 
address should a  subject be considered  lost to follow -up. All  contact attempts 
should be documented in the subjectâ€™s source  records.  
3. Death  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 44 of 63 8. STUDY ASSESSMENTS AND PROCEDURES  
Written informed  consent must be provided before any study- related procedures/assessments are 
performed. Refer to the Schedule of Events  (Section  1.3) for procedures/ assessments and  timing.  
8.1. General Study Assessments  
General study assessments are outlined in Table 1.  
 Table 1: General Study Assessments  
Assessment  Details  
Review of inclusion/exclusion criteria  Eligibility is to be confirmed prior to the first dose of study treatment 
(see Section  5.1 and Section  5.2 for eligibility criteria ).  
Medical history , demographics  Demographic s (age, gender, race, ethnicity), r elevant medical history 
(past and concurrent).  
Height and body weight  Height is measured  at screening only (for body mass index [ BMI ] 
calculation).  
Prior and c oncomitant 
medication s/concomitant therapy  Record all medications that are taken  within 30 days prior to informed 
consent and throughout the study. 
Structured Clinical Interview for 
DSM -5 â€“ Clinical Trials Version  
(SCID -5-CT) Diagnostic Interview  Subjects will be screened to determine whether they  fulfill the criteria 
for diagnosis of MDD  according to the SCID -5-CT, which will be 
performed by a qualified, trained, validated healthcare professional . 
SAFER Interview  The interview w ill be conducted by a central rater for determination of 
eligibility.  The SAFER inventory for confirmation of eligibility 
(diagnosis, severity, and treatment history) includes confirmation of MDD using the MADRS, and use of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (MGH 
ATRQ) for asse ssment of current antidepressant therapy ( ADT ), 
adequacy of duration and dose of prior and current ADT, as well as 
degree of improvement, so that only patients with inadequate response (<50% improvement) are included.  
Site staff will schedule the interview for the central rater, who will contact the patient as scheduled and conduct the interview.  Results will 
be communicated to the site prior to Day 1.  
Childhood Trauma Questionnaire (CTQ ) Retrospective measure of childhood trauma containing 5 subs cales 
(emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical neglect ). Assessed at screening only.  
8.2. Efficacy Assessments 
Efficacy assessments are outlined in  Table 2. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 45 of 63 Table 2: Efficacy Assessments  
Assessment  Details  
Montgomery- Ã…sberg Depression 
Rating Scale (MADRS)  10 questions, each rated on a 7- point scale, to stratify severity of 
depressive episodes in adults.  
Includes change from baseline in the MADRS total score at all time 
points, percentage of MADRS responders (â‰¥50% reduction in total score), percentage of MADRS remitters (total score â‰¤10).  
The same rater should perform MADRS assessments throughout the study on a given patient when possible.  
Hamilton Anxiety Scale (HAM -A) 14 questions, each rated on a 5- point scale, to rate the level of anxiety.  
Includes change in HAM -A total score from baseline to Day  56, 
and change in total score at all time points . 
Clinical Global Impression -Severity 
(CGI -S) 7-point scale for clinician to rate the severity of the patientâ€™s illness at 
the time of assessment, relative to past experience with patients having the same diagnosis.  
Includes change in CGI -S total score from baseline to Day  56, 
and change in total score at all time points . 
The same rater should perform CGI assessments throughout the study on a given patient when possible.  
Clinical Global Impression -
Improvement (CGI- I) 7-point scale for clinician to assess how much the patientâ€™s illness has 
improved or worsened relative to a baseline state.  
Includes percentage of CGI -I improvers (â€œVery much improvedâ€ or 
â€œMuch improvedâ€) at all time points . 
The same rater should perform CGI assessments throughout the study on a given patient when possible.  
Patient Global Impression of 
Improvement (PGI- I) 7-point scale used to evaluate patient satisfaction with tr eatment.  
Includes PGI -I score at Day  56, and score at all time points.  
Hamilton Depression Rating Scale (6 -
item) (HAMD -6) 6-point scale derived from the 17- item Hamilton Rating Scale for 
Depression  to evaluate severity of depression.  Subjects will complete 
the HADM -6 twice a day for three days per week.  
General Anxiety Disorder  (7-item) 
(GAD- 7) 7-point scale to measure the level of anxiety.  Subjects will complete 
the GAD- 7 twice a day for three days per week.  
Short Form -Health Survey (36 -item)  
(SF-36) 36-question survey self -reported measure of physical and mental 
health.  
Include s total score from baseline to Day  56, and  change from baseline 
in total score at all time points . 
8.3. Safety Assessments  
Safety assessments are outline d in Table 3. 
Table 3: Safety Assessments 
Assessment  Details  
AE monitoring  Serious adverse events (SAEs) that occur subsequent to the signing of the 
informed consent (i.e., during the Screening Period ) as a result of study 
participation will be recorded. All adverse events (AEs) and SAEs  occurring 
subsequent to the first dose of study drug on Day 1 will be recorded. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 46 of 63 Assessment  Details  
Physical examination  Physical examination and review of relevant systems at screening, including 
body weight and height.  
Vital signs  Oral temperature (Â°C), respiratory rate, heart rate, and blood pressure (supine and standing) . 
12-lead electrocardiograms  A standard 12 -lead ECG (ventricular rate, RR, PR, QRS, QT, QTcB, and QTcF) 
will be performed by the Investigator or designee after the subject has been in the supine position for at least 5 minutes at specified visits. The subject must be in 
a supine posit ion while the ECG is obtained. Electrocardiogram tracings will be 
reviewed and interpreted by a qualified clinician. Electrocardiogram tracings and 
results with Investigatorâ€™s interpretation are to be included and summarized in the subjectâ€™s study records.  
The date, time, subject  demographics (e.g., age, and sex) and subject number  
should be recorded on the ECG.  
Ophthalmic examination  Ophthalmic exam , including slit- lamp imaging,  may be performed by a n 
appropriately trained and qualified individual as delegated by the PI and documented in the Study Delegation Log.  However, a licensed ophthalmologist 
or optometrist must oversee this work and will make the determination on subject eligibility as per inclusion criteria #4.  Additional slit lamp imaging of the 
lenses of both eyes may be performed  during the treatment period  and sent to a 
central reader for assessment using the LOCS III as per investigatorâ€™s discretion.  
Slit lamp imaging performed during the study showing a change of greater than or equal to 0.5 on the LOCS III scale and any changes determined by the investigator to be clinically significant will be recorded and considered an adverse event of special interest.  
Clinical significance  is defined as  a class I lens event  (minimal change)  [increase 
from baseline in the LOCS III grade of â‰¥0.5 (Nuclear Opalescence), â‰¥0.5 (Cortical) or â‰¥0.5 (Posterior Subcapsular)] and any changes considered to be clinically significant (e.g., incidence of cataract).  
Columbia -Suicide Severity 
Rating Scale (C -SSRS)  Rating scale used to assess suicidal ideation and behavior.  
The â€œBaseline/Screeningâ€ C -SSRS form will be completed at screening. The 
â€œSince Last Visitâ€ C -SSRS form will be completed at any time of day at all 
subsequent time points . 
Safety laborat ory tests  See Table  4. 
Abbreviations: AE  = adverse event; ECG  = electrocardiogram; ET = Early Termination ; PK = pharmacokinetic; 
QTcF  = QT interval corrected for heart rate using Fridericiaâ€™s formula. 
8.3.1. Laboratory Assessments 
See Table 4 for the list of clinical laboratory tests to be performed and the Schedule of Events  
(Section  1.3) for timing and frequency. 
Table 4: Laboratory Assessments 
Laboratory Test Parameters  
Hematology  Hemoglobin, hematocrit, RBC  (including mean corpuscular hemoglobin, mean 
corpuscular volume, mean corpuscular hemoglobin concentration) , WBC with 
differential (neutrophils [absolute count] and lymphocytes, monocytes, eosinophils, basophils), and platelet count.  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 47 of 63 Laboratory Test Parameters  
Coagulation  PT, INR, aPTT.  
Serum  chemistry   Non-fasting: albumin, alanine aminotransferase ( ALT ), aspartate 
aminotransferase (AST ), alkaline phosphatase, amylase/lipase, bicarbonate, 
bilirubin (total and direct), BUN (urea where BUN not tested), calcium, chloride, 
creatinine, glucose, magnesium, phosphorus, potassium, sodium, and total 
protein. Subjects found to have treatment -emergent laboratory toxicity of 
Grades  3 or 4 will be monitored at least weekly until resolution.  
Urinalysis  pH, protein,  ketones, bilirubin, nitrite, blood, leukocytes, specific gravity, 
urobilinogen. Reflex to microscopic exam when positive for protein, blood, 
nitrite, or leukocytes.  
Pregnancy test  Urine pregnancy test will be conducted in only female subjects of childbea ring 
potential. Female subjects who prematurely discontinue will have a pregnancy 
test performed at the ET visit.  
Serology  HBsAg, HCV Ab , HIV antibody  
Urine  drug and alcohol  
screen  Urine  toxicology for selected drugs  of abuse  (barbiturates, amphetamines, 
cocaine, opioids)  and breath test  for alcohol.  
Plasma,  saliva,  and 12-hour 
urine  collection  for 
measurement  of cortisol 
level ,  Study site personne l will dispense the equipment and train subjects on how to 
collect a 12- hour urine collection for measuring cortisol level.  
Saliva collection at screening should be a morning sample.  
Abbreviations: ALT  = alanine aminotransferase; aPTT  = activated partial thromboplastin time; AST = aspartate 
aminotransferase; BUN  = blood urea nitrogen; ET = early termination; HBsAg  = hepatitis B surface antigen; 
HCV Ab = hepatitis C virus  antibody ; HIV = human immunodeficiency virus; INR  = International Normalized Ratio; 
PT = prothrombin time; RBC  = red blood cell; WBC  = white blood cell.  
 
8.3.1.1.  Reporting and Evaluation of Laboratory Test Results  
Adverse event s will be collected from the first dose of ANC -501, therefore the screening 
laboratory results are considered ba seline. All laboratory test results ( except for those at 
screening , which are considered baseline) must be reviewed for clinical significance by the 
Investigator. Laboratory test results outside the normal range (hematology, coagulation, 
chemistry, urinalysis) that worsen in  severity  from baseline and are deemed  clinically significant 
by the Investigator should be reported as AEs. A  new laboratory abnormality resulting in study 
drug interruption, dose reduction, treatment discontinuation, intervention, or otherwise having an 
impact  on the subject  should be reported as an AE, unless it is part of a  clinical diagnosis already 
reported as an AE.  
All laboratory values outside the normal range are to be evaluated.  
8.3.1.2. Repeat Testing  
Repeat testing of any clinically significant laboratory test will be  performed  until the value 
returns to within the normal range, returns to the baseline level, or  clinically stabilize s. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 48 of 63 8.3.2. COVID- 19 Pandemic Accommodations  
The US Food and Drug Administration (FDA) has issued guidance to provide general 
considerations to assist sponsors in assuring the safety of study participants, maintaining 
compliance with Good Clinical Practice ( GCP ), and minimizing risks to trial integrity d uring the 
coronavirus disease 2019 ( COVID -19) public health emergency. It is recognized that the 
COVID- 19 public health emergency may impact the conduct of clinical trials. Challenges may 
arise, for example, from quarantines, site closures, travel limitations, interruptions to the supply 
chain for the investigational product, or other considerations if site personnel or study subjects 
become infected with COVID -19. These challenges may lead to difficulties in meeting 
protocol -specified procedures, including administering or using the investigational product or 
adhering to protocol -mandated visits and laboratory/diagnostic testing. Protocol modifications 
may be required, and there may be unavoidable protocol deviations due to COVID -19 illness 
and/or COVID -19 public health control measures. EmbarkNeuro, or its affiliated clinical 
research organizations ( CROs ), representatives, and clinical sites may need to make decisions 
regarding continuing study recruitment, continuing use of the investigational product for subjects 
already participating in the study, and the need to change subject monitoring during the study. 
EmbarkNeuro  acknowledges that it is critical that study subjects  are kept informed of changes to 
the study and monitoring plans that could impact them. EmbarkNeuro , following consultation 
with clinical investigators and Institutional Review Boards ( IRBs ), may determine that the 
protection of a subjectâ€™s  safety, welfare, and rights is best served by continuing a subject  in the 
study as per the protocol or  by discontinuing the administration or use of the investigational 
product or even participation in the study. In addition, home health services may be utilized in this study per FDA guidance to enable subjects  to remain on study and have testing performed 
per the protocol. It is generally the practice of EmbarkNeuro  to implement protocol changes only 
after review and approval by the IRB, and in some cases, by the FDA. EmbarkNeuro or its 
affiliated CROs and clinical investigators will engage with IRBs as ea rly as possible when urgent 
or emergent changes to the protocol or informed consent are anticipated as a result of COVID- 19. Such changes to the protocol or investigational plan to minimize or eliminate 
immediate hazards or to protect the life and well- being of research subjects  (e.g., to limit 
exposure to COVID -19) may be implemented without IRB approval or before filing an 
amendment to the Investigational New Drug (IND)  application , but will be reported afterwards. 
These considerations are intended to remain in effect only for the duration of the public health emergency related to COVID -19. 
8.4. Adverse Events, Serious Adverse Events, and Other Safety 
Reporting  
8.4.1. Definition of Adverse Event  
AE Definition  
An AE is defined as any untoward medical occurrence in a clinical study subject administered 
a pharmaceutical product  and does not necessarily have a causal relationship with this  
treatment . An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a treatment , whether or not related to the treatment. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 49 of 63 8.4.1.1. Events Meeting the Adverse Event Definition  
Events Meeting the AE Definition  
â€¢ Laboratory test results outside the normal range (hematology, coagulation, clinical 
chemistry, or urinalysis) or other safety assessments (e.g., ECG, vital signs measurements, 
questionnaires), including any that worsen in severity  from baseline, which are considered 
clinically significant in the medical and  scientific judgement of the Investigator. 
â€¢ Exacerbation of a chronic or intermittent pre-existing condition resulting in an increase 
in severity . 
â€¢ Condition detected or diagnosed that is new in onset or increased in severity from the 
baseline condition. 
â€¢ Signs, symptoms, or the clinical sequelae of a suspected intervention-intervention interaction.  
â€¢ Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication. An overdose or incorrect administration of study treatment is not itself an AE, but it may result in an AE.  
8.4.1.2. Events NOT Meeting the Adverse Event Definition  
Events NOT  Meeting the AE Defin ition  
â€¢ Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the patientâ€™s condition. 
â€¢ The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the patientâ€™s condition. 
â€¢ Medical or surgical procedure (e.g., endoscopy, appendectomy). The condition tha t leads 
to the procedure is the AE. 
â€¢ Pre-planned medical or surgical procedures, or pre-planned treatments or hospital 
admissions used to facilitate study visit arrival or procedures. 
â€¢ Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). 
â€¢ Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at  the start of the study that do not worsen in severity . 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 50 of 63 8.4.2. Definition of Serious Adverse Event  (SAE)  
An SAE is defined as any untoward medical occurrence that at any dose:  
1. Results in death 
2. Is life -threatening  
â€¢ The term â€œlife -threateningâ€ refers to an event in which the patient was at risk of death 
at the time of the event. It does not refer to an event which hypot hetically might have 
caused death if it were more severe.  
3. Requires inpatient hospitalization or prolongation of existing hospitalization  
â€¢ In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physicianâ€™s office or outpatient setting. Complications that occur during hospitalization are AEs. 
If a complication prolongs hospitalizati on or fulfills any other serious criteria, the event 
is serious. When in doubt as to whether â€œhospitalizationâ€ occurred or was necessary, the AE should be considered serious.  
â€¢ Hospitalization for preplanned procedure and/or study- related treatment or proced ure 
that did not worsen from baseline is not considered an AE.  
â€¢ Hospitalization for elective treatment of a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
4. Results in persistent disability/incapacity  
â€¢ Disability  is defined as a substantial disruption of a personâ€™s ability to conduct normal 
life functions, either reported or per clinical judgment. 
5. Is a congenital anomaly/birth defect (if exposure to product just before conception or during pregnancy resulted in a n adverse outcome in the child)  
6. Other situations (Important medical events):  
â€¢ Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediate ly life -threatening or result in death or hospitalization but may jeopardize the 
participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious (e.g., invasive or malignant cancers, intensive treatment in an emergency room 
or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, development of drug dependency or drug abuse).  
â€¢ Is any other important medical event that based upon appropriate medical judgment may jeopardize the patient or may require medical or surgical intervention to prevent one of the other outcomes listed in the definitions above (e.g., may not result in death, be life threate ning, or require hospitalization).  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 51 of 63 8.4.3. Time Period for Collecti ng AE and SAE Information 
All AEs will be recorded from study drug administration on Day 1  until Day 112 (see 
Section  8.3.1.1 regarding laboratory- associated AE assessments).  
Serious adverse events that occur subsequent to the signing of the informed consent (i.e., during 
the Screening Period ) as a result of study pa rticipation will be recorded, as well as all SAEs  
occurring from study drug administration on Day 1 until Day 112. If the Investigator bec omes 
aware of an SAE that is possibly  related to the investigational drug treatment at any time after 
the final follow -up visit, the Sponsor should be notified immediately (i.e., within 24 hours). 
Report the SAE using the method described below. 
8.4.4. Recording of Adverse Events and/or Serious Adverse Events  
8.4.4.1. Terms of Reported Adverse Events  
All AEs will be recorded  in the elect ronic case report form (e CRF ), including start and stop 
dates, severity/grade, study drug relationship, and event outcome. 
The Investigator should attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible,  the diagnosis (not the individual 
signs/symptoms) should be documented as the AE.  
8.4.4.2. Detection of  Adverse Events and Serious Adverse Events  
The Investigator will record  all observed and reported AEs. In addition, each subject  will be  
questioned with regard to AEs , but not occurrence of specific AEs.  
8.4.4.3. Severity of Adverse Events  
Severity of AEs will be graded as:  
â€¢ Mild: event may be noticeable to the subject; does not influence daily activities; usually does not require intervention 
â€¢ Moderate: event may be of sufficient severity to make the subject uncomfortable; 
performance of daily activities may be influenced; int ervention may be needed 
â€¢ Severe: event may cause severe discomfort; usually interferes with daily activities; 
subject may not be able to continue in the study; treatment or other intervention usually 
needed  
If the severity of an AE changes more than once a day, the maximum severity for the event should be listed. If the severity changes over a number of days, these mini- events or changes 
should be recorded separately (i.e., having distinct onset dates). 
8.4.4.4. Causal Relationship with Study Treatment  
Assessment of Causality 
â€¢ The Investigator is obligated to assess the relationship between study drug and each 
occurrence of each AE/SAE . A â€œreasonable possibilityâ€ of a relationship conveys that 
there are facts, evidence, and/or arguments to suggest a causal relationship. Investigators 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 52 of 63 Assessment of Causality 
should use their knowledge of the subjectâ€™s medical/disease history, the specific 
circumstances of the event, and potential alternative causes to determine if an AE is 
considered related to the study drug: 
o Definitely : The event has a plausible time relationship to drug intake, cannot be 
 explained by the disease under study or other drugs, or has a definitive  pharmacologic relationship to the study drug. 
o Probably: The event has a reasonable time relationship to drug intake, and is  unlikely to be attributed to the disease under study or other drugs. 
o Possibly: The event has a reasonable time relationship to drug intake, and could also  be attributed to the disease under study or other drugs. 
o Not related:  The event has a time relationship to drug intake that makes a relationship 
 impossible, or is clearly attributable to the disease under study, to other  drugs, or to other factors or events. 
â€¢ The Investigator will consult the Investigatorâ€™s Brochure (IB) in the assessment and  will 
use clinical judgment in the determination.  
â€¢ For each AE/SAE, the Investigator must  document in the medical notes that the event has 
been reviewed and an assessment of causality  provided. 
â€¢ There may be situations in which an SAE has occurred, and the Investigator has minimal 
information to include in the initial report to the Sponsor or designee. However, it is very important that the I nvestigator always assessment causality for every event before the 
initial transmission of the SAE data.  The Investigator may change causality determination 
in light of follow-up information, and  send an SAE follow-up report with the updated 
causality assessment. 
8.4.4.5. Follow- up of Adverse Events  
Adverse event s should be followed until the AE has resolved, returned to baseline, or stabilized; 
withdrawal of consent; or death. 
8.4.5. Reporting of Serious Adverse Events  (SAE)  
The Sponsor or designee must be notified using an SAE R eport form within 24 hours of the 
Investigator becoming aware of an SAE . This timeframe is also applicable to follow -up 
information for previous reported SAEs. 
The Investigator is obligated to obtain supplemental measurements and/or evaluations as 
medically indicated or as requested by the Sponsor or designee to elucidate the nature and/or 
causality of the event as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, ra diographic imaging, or consultation with other 
health care professionals.  
The SAE  Report form and redacted medical records should be submitted to 
safety@safeharborpv.com  or
 via fax to (919) 591-0004. 
Follow-up information will be reported in the same method as above. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 53 of 63 8.4.6. Reporting of Deaths  
Death must be reported if it occurs during the SAE reporting period as noted in Section  8.4.3. 
8.4.7. Pregnancy  
Details of all pregnancies in female subjects or in female partners of male subjects (after 
appropriate consent for use of medical information has been obtained) will be reported to the Sponsor or designee at the email noted in Section  8.4.5 within 24 hours of the Investigatorâ€™s 
awareness, using a Pregnancy Report form. 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported as such. 
The subject/pregnant female partner  will be followed to determine the outcome of the pregnancy. 
The Investigator will collect follow -up information on the subject/pregnant female partner  
and the neonate, and forward to the Sponsor or designee. 
Any female subject who becomes pregnant while participating in the study will discontinue 
study drug. 
8.4.8. Overdose  
Refer to Section  6.7 for information regarding ANC -501 overdose. 
8.4.9. Events of Special Interest - Lens Opacity  
Lens opacity is an event of special interest in this study. Slit lamp imaging  of the lenses of both 
eyes will be taken at Screening, Day 56, follow-up Day 70 and follow-up Day 112 and sent to a 
central reader for assessment using the LOCS III. Additional s lit lamp imaging may be 
performed during the treatment period and sent to a central reader for assessment using the LOCS III as per the investigatorâ€™s discretion. 
 LOCS III scale changes from baseline of â‰¥0.5 (Nuclear Opalescence), â‰¥0.5 (Cortical). â‰¥ 0.5 
(Posterior Subcapsular) and any changes considered to be clinically significant (e.g., incidence of 
cataract) are considered adverse events and events of special interest.  Any changes considered to 
be clinically significant  will be immediately reported to the Sponsor and/or designee within 24 
hours of becoming aware of the event whether or not the event is deemed to be related to investigational product. 
8.5. Ph
 armacokinetics  
The serum concentrations and calculated PK parameters of ANC -501 will be assessed based on 
blood samples collected from subjects during the study. Collection time points for the assessment 
of PK  are detailed in the Schedule of Events ( Section  1.3). Additional details regarding sample 
collection timing will be included in a separate Laboratory Manual. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 54 of 63 8.6. Biomarker Evaluations  
Blood samples will be collected for future exploratory biomarker and genetic analysis. 
Collectio n time points are detailed in the Schedule of Events ( Section  1.3).  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 55 of 63 9. STATISTICAL CONSIDERATIONS  
9.1. Statistical Hypotheses  
No formal statistical hypotheses testing will be performed.  
9.2. Sample Size Determination  
Up to 20 subjects will be enrolled. The sample size was selected based on clinical and not 
statistical considerations.  
9.3. Analysis Populations  
For the purposes of analysis, the following populations  are defined:  
Table  5: Definitions of Analysis Populations  
Analysis Population  Definition  
Safety  Includes all subjects who received at least one dose of ANC -501. 
This is the primary population for exposure and safety analyses.  
Efficacy  Includes all subjects who received at least one dose of ANC -501 
and have at least one post -baseline efficacy evaluation . This is the 
primary population for efficacy endpoints . 
9.4. Statistical Analyses  
9.4.1. General Considerations  
A Statistical Analysis Plan (SAP) will be prepared as a separate document. The SAP will include a more technical and detailed description of the planned st atistical summaries and will be 
finalized prior to closing of database . 
Continuous endpoints will be summarized with n, mean, standard deviation, median, minimum, and maximum. In addition, change from baseline values will be calculated at each time point a nd 
summarized descriptively. For categorical endpoints, descriptive summaries will include counts and percentages.  
Methodology and analyses for missing data will be defined in the SAP.  
9.4.2. Analysis of Safety 
The Safety Population will be used to provide descri ptive summaries of safety data. Treatment-
emergent adverse events will be classified by type, incidence, severity, and causality. The overall incidence of adverse events will be summarized by Medical Dictionary for Regulatory Activities 
(MedDRA) System Org an Class (SOC) and Preferred Term (PT). Data for vital signs, clinical 
laboratory tests, ECG, physical examinations, and concomitant medication usage will also be 
summarized.  
Changes in LOCS  III will be assessed from Screening to Day 56, 70 and 112 visits.  An increase 
from baseline in the LOCS III grade of â‰¥0.5 (Nuclear Opalescence), â‰¥0.5 (Cortical) or â‰¥0.5 (Posterior Subcapsular)] in either eye and any changes considered to be clinically sig nificant 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 56 of 63 (e.g., incidence of cataract) as per the ophthalmologist or optometrist will be reported as an 
adverse event and an event of special interest.  
Suicidality  data collected using the C -SSRS at baseline and at each visit during the active 
Open -Label Treatment Period  will be listed for all subjects. The C -SSRS listings will include 
behavior type and/or category for suicidal ideation and suicidal behavior of the C -SSRS.  
9.4.3. Analysis of Efficacy 
The Efficacy Population will be used to analyze efficacy data. Efficacy data will be analyzed using appropriate descriptive statistics and pre -specified statistical methods, as well as other data 
presentation methods where appl icable; subject listings will be provided for all efficacy data. 
Efficacy data will be summarized descriptively.  
9.4.4. Analysis of Pharmacokinetics  
Plasma concentrations of ANC -501 will be listed by individual and summarized by treatment in 
tabular format using descriptive statistics (number, arithmetic mean, standard deviation, median, minimum, maximum, geometric mean, and geometric coefficient of variation). ANC -501 plasma 
concentrations will be plotted against time points by dose level/cohort (mean and individual).  
ANC -501 concentration data may be combined with concentration data from other studies to 
build a PK model. 
9.5. Interim Analysis  
No formal interim analysis is planned.  
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 57 of 63 10. ADMINISTRATIVE CONSIDERATIONS  
10.1. Protocol Compliance /Deviations 
The Investigator agree s to conduct the study in compliance with the protocol and all  
amendments . Any protocol deviation(s) should be recorded in the source documents along with 
a clear description of the deviation(s) and cause. 
10.2. Study Termination  
Premature termination  of this study may occur  because of a regulatory authority  decision,  change 
in opinion of the Institutional Review Board ( IRB), issues with study drug, or at the discretion of 
the Sponsor. In addition, the Sponsor retains the right to suspend or discontinue ANC -501 
development at any time. 
The Sponsor will notify the Investigator i f the study is prematurely terminated. T he Investigator 
must promptly contact all subjects  to arrange final study visit(s) and procedures, as directed by 
the Sponsor. 
10.3. Case Report Forms  
An eCRF is required f or each enrolled subject. For screen failure subjects, a minimal set of data 
will be collected as noted in Section  5.4. Data entered into the eCRF must be consistent with the 
source documents. 
The Investigator has ultimate responsibility for the collection and reporting of all data entered 
in the eCRF and any other data collection forms, and will be electronically signed by the 
Investigator to attest that the data contained in  the e CRF are accurate. 
10.4. Source Documents  
Source documents provide evidence for the existence of the subject and substantiate the integrity 
of the data collected. Source documents (e.g., hospital records, patient hard- copy/electronic files, 
clinical/office charts, pharmacy dispensing records, X- rays) are filed at the Investigatorâ€™s site.  
Data entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request 
previous medical records or transfer records, depending on the study. Also, current medical 
records must be available.  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study 
agreements, International Council for Harmonisation Good Clinical Practice guideline E6 
(ICH  GCP) , and all applicable regulatory requirements. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 58 of 63 10.5. Data Protection  
Subjects will be assigned a unique identifier by the Sponsor. Any subject records or datasets that 
are transferred to the Sponsor will contain the identifier only; names or any information which 
would make the subject identifiable will not be transferred.  
The subject must be informed that his/her personal study- related data will be used by the 
Sponsor in accordance with local data protect ion law. The level of disclosure must also be 
explained to the subject, who will be required to give consent for the data to be used as described in the informed consent form (ICF).  
The subject must also be informed that medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB members, and by inspectors from regulatory authorities. 
10.6. Recordkeeping  
The Investigator agrees to keep and maintain  records that would permit the Sponsor 
and regulatory authorities to evaluate/audit the study. These include the identity of subjects, I RB 
correspondence, original signed ICFs, source documents, the eCRFs, SAE/Pregnancy Report forms, drug storage/accountability/disposition records, and correspondence (e.g., letters , email, 
meeting minutes, telephone call records) with the Sponsor or designee. R ecords should be 
retained by the Investigator for a period of 2 years after the last marketing application approval (or if not approved, for 2 yea rs following the discontinuation of the investigational use) , 
according to the ICH guidelines, local regulations, or as specified in the clinical study agreement, whichever is longer.  
If the Investigator becomes unable to retain study records for any reaso n (e.g., retirement, 
relocation), the y must be transferred to the Sponsor or to a designee acceptable to the Sponsor  
(e.g., another investigator, another institution, or independent third party) . 
10.7. Quality Control and Quality Assurance  
The Sponsor or designee  will conduct periodic visits  or audits  during or after the study to ensure 
that the protocol and GCP are being followed. The monitors may review the drug storage area, study drug stocks, drug storage/ accountability /disposition  recor ds, source documents , and 
regulatory documentation. The Investigator and institution will permit direct access to the 
physical spaces, records, and source documents to perform this verification to the Sponsor  or 
designee  monitors/auditors , IRB member s, and  appropriate regulatory authority inspectors . 
The Investigator must  immediately notify the Sponsor  or its designee  of any regulatory 
inspection notification , will cooperate with the Sponsor or designee  to prepare the study site 
for the inspection, will be present during the inspection along with relevant study staff, will 
allow the Sponsor or designee  to be present during the inspection, and will provide copies of any 
inspection findings. 
10.8. Financial Disc losure  
Investigators and sub- investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 59 of 63 certification or disclosure statements to the appropriate regul atory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 60 of 63 11. ETHICS  
11.1. Ethical Conduct of the Study  
The study will be conducted in accordance wit h legal and regulatory requirements, as well as the 
general principles set forth in the International Ethical Guidelines for Biomedical Research 
Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), 
ICH GCP Guideline s, and the Declaration of Helsinki (World Medical Association 1996 and  
2008). 
In addition, the study will be conducted in accordance with the protocol, ICH GCP, 
and applicable local regulatory requirements and laws.  
11.2. Written Informed Consent  
An informed cons ent form (ICF) meeting the requirements of 21 CFR Â§50, local regulations, 
ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements (where applicable), must be reviewed and approved by the Sponsor, approved by the IRB before use, and available for inspection. 
The Investigator or authorized  representative will explain the nature of the study to the subject  
and answer all questions regarding the study. Subjects  must be informed that their participation 
is voluntary, and if they choose to participate, will be required to sign the approved ICF . The 
medical record must include a statement that written informed consent was obtained before any 
study procedures were performed, along with the date written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF . The original signed 
ICF will be retained in the Investigatorâ€™s records, with a copy provided to the subject.  
Subjects  must be re -consented to the most current version of the ICF during their participation in 
the study. 
11.3. Institutional Review Board/Independent Ethics Committee  
The protocol, protocol amendments, ICF, Investigator â€™s Brochure  (IB) , and other relevant 
documents ( e.g., advertisements) must be submitted to an IRB by the Investigator, and reviewed 
and approved by the IRB before the study is initiated. 
Protocols and any substantial amendments to the protocol will require health authority approval 
prior to initiation e xcept for changes necessary to eliminate an immediate hazard to study 
subjects. Any amendments to the protocol will require IRB approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazar d to study subjects . 
The Investigator will provide written summaries of the status of the study and any other significant safety findings to the IRB annually or more frequently in accordance with its 
requirements, policies, and procedures. At the end of the study, the Investigator will notify the 
IRB of the conclusion of the study and its outcome. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 61 of 63 12. PUBLICATION POLICY  
The Sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will general ly support publication 
of multicenter studies only in their entirety and not as individual site data. 
Authorship will be determined by mutual agreement and in line with International  Committee of 
Medical Journal Editors authorship requirements. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 62 of 63 13. REFERENCES 
1. World Health Organization, Fact Sheet Number 369. 2012. 
2. Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar 
and unipolar disorders relative to subjec ts with other Axis I disorders. Biol Psychiatry . 
1996; 39(10): 896â€“899. 
3. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Giralamo G, et al. Crossnational epidemiology of DSM -IV major depressive episode. BMC Med . 2011; 9: 
90. 
4. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas K, et al . The 
epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS -R). JAMA . 2003; 289(23): 3095â€“3105. 
5. Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F . Depression as a 
risk factor for the onset of type 2 diabetes mellitus. A meta -analysis. Diabetologia. 2006; 
49(5): 837â€“845. 
6. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J  Psychiatry . 2001. 178: 234â€“241. 
7. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 
Acute and longer -term outcomes in depressed outpatients requiring one or several 
treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11): 1905â€“ 1917. 
8. Aguilera G, Rabadan -Diehl C. Vasopressinergic regulation of the hypothalamic -pituitary -
adrenal axi s: implications for stress adaptation. Regul Pept . 2000; 96(1- 2): 23â€“29. 
9. Vale W, Spiess J, Rivier J . Characterization of a 41 -residue ovine hypothalamic peptide 
that stimulates secretion of corticotropin and beta -endorphin. Science. 1981; 213(4514): 
1394â€“1397. 
10. de Winter RFP, van Hemart AM, DeRijk RH, Zwinderman KH, Frankhuijzen- Serievogel 
AC, Wiegant VM, et al. Anxious -retarded depression: relation with plasma vasopressin 
and cortisol . Neuropsychopharmacology . 2003; 28(1): 140â€“147. 
11. van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen- Sierevogel AC, Wiegant 
VM, van der Velde EA, et al. Plasma levels of arginine vasopressin elevated in patients 
with major depression. Neuropsychopharmacology . 1997; 17(4): 284â€“292.  
12. Inder WJ, Donald RA, Prickett TC, Frampton CM, Sullivan PF, Mulder RT, et al. 
Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol Psychiatry . 1997; 42(8): 744â€“747. 
13. Meynen G, Unmehopa UA, van Heerikhuize JJ, Hofman MA, Swaab DF, Hoogendijk WJG.  Increased arginine vasopressin mRNA expression in the human hypothalamus in 
depression: A preliminary report. Biol Psychiatry . 2006; 60(8): 892â€“895. 
14. Purba JS, Hoogendijk WJ, Horman MA, Swaab DF . Increased number of vasopressin-  
and oxytocin- expressing neurons in the paraventricular nucleus of the hypothalamus in 
depression. Arch Gen Psychiatry. 1996; 53(2): 137â€“143. 
EmbarkNeuro   Clinical Study Protocol  
ANC -501  ANC501D0005  
03 March 2023 Version 6.0  Confidential  Page 63 of 63 15. Dinan TG, Lavelle E, Scott LV, Newell -Price J, Medbak S, Grossman AB. Desmopressin 
normalizes the blunted adrenocorticotropin response to cort icotropin- releasing hormone 
in melancholic depression: evidence of enhanced vasopressinergic responsivity. J Clin 
Endocrinol Metab. 1999; 84(6): 2238â€“2240. 
16. Serradeil -Le Gal C, Wagnon J, Valette G, Pascal M, Maffrand JP, Le Fur G. Nonpeptide 
vasopressin rec eptor antagonists: development of selective and orally active V1a, V2 and 
V1b receptor ligands. Prog Brain Res . 2002; 139: 197â€“210. 
17. Lolait SJ, Oâ€™Carroll AM, Mahan LC, Felder CC, Button DC, Young 3rd WS, et al. 
Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci 
USA. 1995; 92(15): 6783 â€“6787. 
18. Griebel G, Stemmelin J, Serradeil- Le Gal C, SoubriÃ© P . Non- peptide vasopressin V1b 
receptor antagonists as potential drugs for the treatment of stress -related disorders . Curr 
Pharm Des . 2005; 11(12): 1549â€“1559. 
19. Serradeil -Le Gal C, et al. Characterization of (2 S,4R)-1-[5-chloro- 1-[(2,4 -
dimethoxyphenyl)sulfonyl] -3-(2-methoxy -phenyl) -2-oxo- 2,3-dihydro- 1H-indol -3-yl]-4-
hydroxy- N,N-dimethyl -2-pyrrolidine carboxamide (SSR149415), a selective and orally 
active vasopressin V 1b receptor antagonist. J Pharmacol Exp Ther . 2002; 300(3): 
1122â€“1130. 
20. Iijima M, Chaki S. An arginine vasopressin V1b antagonist, SSR149415 elicits 
antidepressant -like effects in an olfactory bulbectomy model. Prog  
Neuropsychopharmacol Biol Psychiatry . 2007; 31(3): 622â€“627. 
21. Iijima M, Ito A, Kurosu S, Chaki S . Pharmacological characterization of repeated 
corticosterone injection -induced depression model in rats. Brain Res . 2010; 1359: 75â€“80. 